Ian Keight McNiece

Ian Keight McNiece, PhD.

CURRICULUM VITAE

Personal

Date of Birth: March 22, l954

Place of Birth: Australia

Nationality: Australia and USA

Marital Status: Married, Peggy McNiece

Education

B.Sc. Melbourne University, Melb. Australia l979, Bio­chemistry

M.Sc. (prelim) Melbourne University, l98l, Physiology

Ph.D. Melbourne University, l986, Physiology.

Appointments

Pre-Doctoral:

1973‑1975 Royal Children's Hospital, Melbourne, Australia ‑ Technical Assistant

1975‑1976 Cancer Institute, Melbourne, Australia ‑ Technical Assistant

1977‑1978 Melbourne University, Melbourne, Australia ‑ Technical Assistant

1978‑1985 Cancer Institute, Melbourne, Australia ‑ Senior Research Technologist

PostDoctoral:

1986 Cancer Institute, Melbourne, Australia ‑ Postdoctoral Fellow

1986‑1988 University of Virginia, Charlottesville, Virginia, USA ‑ Postdoctoral Fellow.

1988-1994 Amgen Inc., Thousand Oaks, California, USA - Research Scientist

1994-1997 Amgen Inc, TO, CA, USA - Laboratory Head, Dept of Developmental Hematology

1995-1997 Head, Amgen Central Laboratory, St Luc University Hospital, Brussels, Belgium.

1997-1998 Joint appointment: University of California at Santa Barbara, California, USA - Adjunct Professor, Dept. Of Molecular, Cellular and Developmental Biology.

1997 - 2002 University of Colorado Health Sciences Center, Denver CO, USA - Professor of Medicine and Director of Research, Bone Marrow Transplant Program.

1997 - 2002 Joint appointment: University of Colorado HSC, Department of Pharmacology.

1999 - 2002 Joint appointment: University of Colorado HSC, Department of Immunology

2002 Director of Stem Cell Biology Program, University of Colorado HSC

2003 - 2007 Professor of Oncology, Johns Hopkins University, Baltimore, MD

2003 - 2007 Director of Cell Therapy Laboratory, Johns Hopkins University, Baltimore, MD

2004 - 2006 Director of the Division of Biomedical Science, Johns Hopkins in Singapore, Singapore

2004 - 2006 CEO, Johns Hopkins Singapore, Singapore.

2007 - 2012 Professor of Medicine, Division of Cardiology, University of Miami, Miami, FL

2007 - 2012 Director, Experimental and Clinical Cell-Based Therapies Program, Stem Cell Institute, University of Miami, Miami, FL.

2011 - 2012 Laboratory Director, Stem Cell Processing Laboratory, Stem Cell Transplant Program, University of Miami, Miami, FL.

2012 - 2016 Professor of Medicine, Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX

2012 - 2016 Director, Cell Therapy Laboratory, Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.

2016 - present Consultant, CellMed Consulting, Miami, FL

2016 - 2017 VP Clinical Manufacturing, Cellenkos Inc, Houston, TX

2016 - 2017 Acting CSO, Biocardia Inc, San Carlos, CA

2017 - present CSO, Biocardia Inc, San Carlos, CA

2017 - present CSO and Founder, Oncocyclist Biotech, Miami, FL

2017 - present VP of Research & Development, Aegle Therapeutics, Miami, FL

Societies

American Society for Blood and Marrow Transplantation, 1995 - present

American Society of Hematology, 1990 - present

Australian & New Zealand Cell Biology Society, l982 ‑ 1988

European Hematology Assoc, 1995-2008

International Society for Experimental Hematology, l985 ‑ 2007

International Society for Cellular Therapy (formerly ISHAGE), 1995 - present

International Society for Stem Cell Research, 2003 - 2009

Society of Leukocyte Biology, 1992-1997

Editorial Appointments

Editorial Board, International Journal of Cell Cloning (1992-1993).

Editorial Board, Stem Cells (1993-2007)

Associate Editor, Experimental Hematology (1998-2003)

International Editorial Board, Journal of Clinical and Experimental Hematopathology (2000 - present)

Editorial Board, Experimental Hematology (2004-2006)

Editorial Board Member - Cytotherapy, 2011 - 2013.

Editorial Board Member - Journal of Regenerative Medicine, 2012 - 2016.

Editor-in-Chief - Journal of Regenerative Medicine, 2012 - 2016.

Editorial Board, Molecular and Cellular Therapies Journal, 2013 - present.

Other

ISHAGE Ex Vivo Expansion Committee, 1997 - 2004.

Scientific Advisory Board - 28th Annual Meeting of ISEH, 1999.

Laboratory Inspector - FACT Transplant Program Accreditation 1998- present.

Program Advisory Board - 10th Int Symposium on ABMT, 2000.

Membership Committee of ISEH, 2000 to 2002.

Ad hoc reviewer, Hematology I Study Section, NIH

Ad hoc reviewer, Regenerative Medicine Study Section, NIH

Ad hoc reviewer, NIAID, NIH

Ad hoc reviewer, NCI, NIH

Ad hoc reviewer and committee chair, NYSTEM grant review

Councillor of ISEH, 2002 - 2005

ISCT Hematopoietic Stem Cell Committee - Chair, 2004 - 2011.

Member - Advisory Board of the Faculty of Medicine, Dept of Medicine, Johns Hopkins Univ, 2004 to 2006

Committee Member - FACT Standards Committee, Cell Processing Lab Subcommittee, 2004 - present.

ISCT Annual meeting, Organizing committee 2005

Principal Investigator - FDA IND#12379 Ex vivo expanded Mafosfamide purged CD34+ cells, approved August, 2005.

Principal Investigator - FDA IND#12658 Ex vivo expanded CD133+ cord blood cells, approved October 2005.

Director - Board of Directors ES International, Singapore, 2006 - 2007.

ISCT Annual meeting, Organizing committee 2006.

Faculty member, Pathobiology Graduate Program, Johns Hopkins University, Baltimore, MD 2006-2007.

Member Scientific Advisory Board, National Stem Cell Inc, 2006 - present

ISCT Annual meeting, Organizing committee 2007.

ISCT 2008 Annual meeting, Maimi, FL - Co-Chair

Chief Scientific Officer and Board Member - Proteonomix Inc, 2009 - 2014.

ISCT Annual meeting, Organizing committee 2009.

Chairperson - Univ of Miami ESCRO Committee 2009 -2012.

Director - Board of Directors Foundation for the Accreditation of Cellular Therapy (FACT), 2010 - present

Vice-Chair, Institutional Review Board, MD Anderson Cancer Center, Houston, TX 2015 - 2016

Co-Chair, Cell Graft and Manipulation Committee, CIBMTR, 2017- present

Expertise in Cellular Therapy

1990-1997 Amgen Inc., Thousand Oaks, California, USA

As Laboratory Head of the Developmental Hematology Group I led research, preclinical and clinical development of projects including:

i) mobilization of PBPC with G-CSF and SCF

ii) development of the AmCell cell selection device - this instrument led to the CliniMACS which is currently in clinical use for cell selection

iii) ex vivo expansion of cord blood and PBPC

1995-1997 Head, Amgen Central Laboratory, St Luc University Hospital, Brussels, Belgium.

Clinical trial support was implemented for Amgen Europe for cell therapy trials.

1997-2002 University of Colorado Health Sciences Center, Denver CO, USA

Director of Research, Bone Marrow Transplant Program.

In collaboration with Dr Shpall I developed clinical trials for studies on ex vivo expansion of PBPC and also on ex vivo expansion of cord blood cells.

2003- 2007 Director of Cell Therapy Laboratory, JHMI, Baltimore, MD

As Director of the Cell Therapy Laboratory of the BMT Program at Johns Hopkins University I was responsible for all cell processing for cellular therapy clinical trials at Hopkins

My own research resulted in initiation of 2 clinical trials under FDA INDS:

Principal Investigator - FDA IND#12379 Ex vivo expanded Mafosfamide purged CD34+ cells, approved August, 2005.

Principal Investigator - FDA IND#12658 Ex vivo expanded CD133+ cord blood cells, approved October 2005

2007- 2012 Director, Experimental and Clinical Cell-Based Therapies Program, Stem Cell Institute, University of Miami, Miami, FL.

As Director of this Program I have been responsible for the design, building of a cGMP and cGTP facility. The Program has received FACT accreditation and CLIA certification. Ongoing clinical trials supported by the facility include:

i) A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Intramyocardial Injection of Autologous Human Mesenchymal Stem Cells (MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction (MI) Undergoing Cardiac Surgery for Coronary Artery Bypass Grafting (CABG).

ii) A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.

iii) A phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cells versus allogeneic mesenchymal stem cells in patients with chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction.

iv) A phase I/II study of cultured bone marrow-derived cells for the treatment of chronic wounds

v) A phase I/II study of allogeneic versus autologous MSCs for the treatment of chronic wounds.

vi) Mobilization of stem cells with G-CSF and Mozobil in patients with end stage liver disease.

Other projects developed for submission for INDs include:

i) Tumor lysate matured dendritic cells for treatment of glioblastoma and sarcoma.

ii) Ex vivo expansion of cord blood mononuclear cells on MSCs

iii) Mesenchymal stem cells in neonatal lung disease of prematurity.

Activities with the Foundation for Accreditation of Cellular Therapies(FACT)

1998 - present Laboratory Inspector - FACT Transplant Program Accreditation

Inspected more than 25 laboratories for FACT accreditation

2010 - present Director - Board of Directors FACT

2010 - present Chairperson, FACT Regenerative Medicine Task Force

PUBLICATIONS

Peer Reviewed Original Articles

1. Kriegler AB, Bradley TR, Hodgson GS, McNiece IK (198l). Identification of the "factor" in erythrocyte lysates which enhances colony growth in agar cultures. Exp.Hematol. 9(l): 11‑21.

2. McNiece IK, Bradley TR, Kriegler AB, Hodgson GS (l982). A growth factor produced by WEHI‑3 cells for murine high proliferative potential GM‑progenitor colony forming cells. Cell Biology International Reports 6(3): 243‑251.

3. McNiece IK, Kriegler AB, Hapel AJ, Fung MC, Young IG, Bradley TR, Hodgson GS (l984). Recombi­nant interleukin‑3 exhibits synergistic factor activity. Cell.Biol.Int. Reports 8(l0): 8l2.

4. McNiece I, Kriegler A, Bradley R, Hodgson G (l985). Detection of synergistic factor and interleukin‑3 activity in the serum and ascites fluid of mice bearing the WEHI‑3 tumor. Leukemia Res. 9(8): l069‑l074.

5. Williams N, Sparrow R, Gill K, Yasmeen D, McNiece I (l985). Murine megakaryocyte colony stimulating factor: its relationship to interleukin 3. Leukemia Res. 9(l2): l487‑l496.

6. McNiece IK, Bradley TR, Kriegler AB, Hodgson GS (l986). Subpopulations of mouse bone marrow high proliferative potential colony forming cells (HPP‑CFC). Exp.Hematol. l4(9): 856‑860.

7. Bertoncello I, Bartelmez SH, Bradley TR, Stanley ER, Harris RA, Sandrin MS, McNiece IK, Kriegler AB, Hunter SD, Hodgson GS (l986). Isolation and analysis of primitive hemopoietic progenitor cells on the basis of differential expression of Qa‑m7 antigen. J.Immunol. l36(9): 32l9‑3224.

8. Quesenberry P, Song Z, McGrath E, McNiece I, Shadduck R, Waheed A, Baber G, Kleeman E, Kaiser D (1987). Multilineage synergistic activity produced by a murine adherent marrow cell line. Blood 69(3): 827‑835.

9. McNiece IK, Bradley TR, Kriegler AB, Hodgson GS (1987). Detection of murine hemopoietin‑1 in media conditi­oned by EMT6 cells. Exp.Hematol. 15(8):854‑858.

10. McNiece IK, Williams NT, Johnson GR, Kriegler AB, Bradley TR, Hodgson GS (1987). Generation of murine hematopoietic precursor cells from macrophage high‑proliferative‑potential colony forming cells. Exp. Hematol. 15(10):972-977.

11. Kriegler AB, Bradley TR, Hodgson GS, McNiece IK (1987). A colorimetric liquid culture assay of a growth factor for primitive murine macrophage progenitor cells. J.Immunol. Method 103(1):93-102.

12. McNiece IK, Stewart FM, Deacon DM, Quesenberry PJ (1988). Synergistic interactions between hemopoietic factors as detected by in vitro mouse bone marrow colony formation. Exp.Hematol.16:383.

13. McNiece IK, Robinson BE, Quesenberry PJ (1988). Stimulation of murine high proliferative potential colony forming cells by the combination of GM‑CSF and CSF‑1. Blood 72:191.

14. McNiece IK, McGrath HE, Quesenberry PJ (1988). Granulocyte colony-stimulating factor augments in vitro megakaryocyte colony formation by interleukin-3. Exp. Hematol. 16:807.

15. McNiece IK, Kriegler AB, Quesenberry PJ (1989). Studies on the synergistic factor from 5637: comparison to interleukin 1 alpha. Blood 73(4):919.

16. McNiece I, Andrews R, Stewart M, Clark S, Boone T, Quesenberry P (1989). Action of IL3, G-CSF and GM-CSF on highly enriched human hematopoietic progenitor cells: synergistic interaction of GM-CSF plus G-CSF. Blood 74(1):110-114.

17. Isakson PC, McNiece IK, Simpson L, Quesenberry PJ (1989). Proliferation of activated B lymphocytes induced by products of a bone marrow stromal cell line. J.Immunol. 142(11):3894.

18. McNiece IK, Stewart FM, Deacon DM, Temeles D.S., Zsebo KM, Clark S, Quesenberry PJ (1989). Detection of a human CFC with a high proliferative potential. Blood 74(2):609-612.

19. Ulich TR, del Castillo J, McNiece IK, Yin S, Irwin B, Busser K, Guo K (1990). Acute and subacute hematologic effects of multi-colony stimulating factor in combination with granulocyte-colony stimulating factor in vivo. Blood 75(1):48-53.

20. Keller JR, McNiece IK, Sill KT, Ellingsworth LR, Quesenberry PJ, Sing GK, Ruscetti FW (1990). Transforming growth factor B regulates primitive murine hematopoietic cell proliferation. Blood 75(3):596-602.

21. Niskanen E, Quesenberry PJ, Shellem TA, McNiece I (1990). Relationship between cells forming colonies in diffusion chambers in vivo (CFU-D) and cells with high proliferative potential (HPP-CFC-1 and 2). Exp. Hematol. 18(4):294-298.­

22. Yan ZJ, Wang QR, McNiece IK, Wolf NS (1990). Dissecting the hematopoietic microenvironment VII: The production of an autostimulatory factor as well as a CSF by unstimulated murine marrow fibroblasts. Exp. Hematol. 18(4):348-354.

23. Woodward TA, McNiece IK, Witte PL, Isakson PC, Baber GB, Quesenberry PJ (1990). Bone marrow stromal cell production of pre-B cell growth factors. Blood 75(11):2130-2136.

24. Ulich TR, del Castillo J, McNiece I, Watson L, Yin S, Andresen J (1990). Hematologic effects of recombinant murine granulocyte-macrophage colony stimulating factor on the peripheral blood and bone marrow. Amer. J. Path. 137(2):369-376.

25. Zsebo KM, Wypych J, McNiece I, Lu H, Smith KA, Karkare SB, Sachdev RK, Yuschenkoff VN, Birkett NC, Williams LR, Satyagal VN, Tung W, Bosselman RA, Mendiaz EA, Langley KE (1990). Identification, purification, and biological characterization of hematopoietic stem cell factor from Buffalo Rat Liver-conditioned medium. Cell 63:195-201.

26. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, Morris CF, McNiece IK, Jacobsen FW, Mendiaz EA, Birkett NC, Smith KA, Johnson MJ, Parker VP, Flores JC, Patel AC, Fisher EF, Erjavec HO, Herrera CJ, Wypych J, Sachdev RK, Pope JA, Leslie I, Wen D, Lin C-H, Cupples RL, Zsebo KM (1990). Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63:203-211.

27. Quesenberry PJ, McGrath HE, Robinson BE, Deacon DH, Clark S, Urdal D, McNiece IK (1991). Multifactor stimulation of megakaryocytopoiesis: effects of interleukin-6. Exp. Hematol. 19:35-41.

28. McNiece IK, Langley KE, Zsebo KM (1991). Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp. Hematol. 19(3):226-231.

29. McNiece IK, Langley KE, Zsebo KM (1991). The role of recombinant stem cell factor in early B cell development: synergistic interaction with IL-7. J. Immunol. 146(11):3785-3790.

30. Ulich TR, del Castillo J, Yi ES, McNiece IK, Yung YP, Zsebo KM (1991). Hematologic effects of stem cell factor in vivo and in vitro in rodents. Blood 78(1):645-650.

31. Ulich TR, del Castillo J, Yi ES, McNiece IK, Zsebo KM (1991). Synergistic myelopoietic effects of SCF in combination with G-CSF and GM-CSF in. Blood 78(8):1954-1962.

32. Kavnoudias H, Jackson H, Ettlinger K, Bertoncello I, McNiece I, Williams N (1992). Interleukin-3 directly stimulates both megakaryocyte progenitor cells and immature megakaryocytes. Exp. Hematol. 20(1):43-46.

33. Williams N, Bertoncello I, Kavnoudias H, Zsebo K, McNiece I (1992). Recombinant rat stem cell factor stimulates the amplification and differentiation of fractionated mouse stem cell populations. Blood 79(1):58-64.

34. McNiece IK, Bertoncello I, Keller JR, Ruscetti FW, Hartley CA, Zsebo KM (1992). Transforming growth factor B inhibits the action of stem cell factor on mouse and human hematopoietic progenitors. Int. J. Cell Cloning. 10(2):80-86.

35. Zsebo KM, Smith KA, Hartley CA, Greenblatt M, Cooke K, Rich W, McNiece IK (1992). Radioprotection of mice by recombinant rat stem cell factor. PNAS 89:9464-9468.

36. Dunlop JM, Firkin F, McNiece IK, Bertoncello I (1993). Accelerated establishment of murine long-term bone marrow cultures by addition of stem cell factor. Exp. Hematol. 21(6):769-773.

37. Tong J, Gordon MS, Srour EF, Cooper RJ, McNiece I, Hoffman R (1993). The in vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells. Blood 82(3):784-791.

38. Briddell RA, Hartley CA, Smith KA, McNiece IK (1993). Recombinant rat stem cell factor synergizes with recombinant human granulocyte-colony stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells which have enhanced repopulating ability. Blood 82(6):1720-1723.

39. Tong J, Gordon MS, Srour EF, Cooper RJ, Orazi A, McNiece I, Hoffman R (1993). The in vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells. Trans Am Assn Phys 151:134.

40. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994). Cloning and characterization of the complementary DNA encoding a novel human pre-B cell colony enhancing factor. Mol.Cell.Biol. 14:1431-7.

41. de Revel T, Appelbaum F, Storb R, Schuening F, Nash R, Deeg J, McNiece I, Andrews R, Graham T (1994). Effects of granulocyte colony stimulating factor and stem cell factor, alone and in combination on the mobilization of peripheral blood cells that engraft lethally irradiated animals. Blood 83(12):3795-3799.

42. Andrews RG, Briddell RA, Knitter GH, Opie T, Bronsden M, Myerson D, Appelbaum FR, McNiece IK (1994). In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons: enhanced circulation of progenitor cells. Blood 84(3):800-810.

43. Yan X-Q, Briddell R, Hartley C, Stoney G, Samal B, McNiece I (1994). Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of SCF plus G-CSF. Blood 84(3):795-799.

44. Fahlman C, Jacobsen FW, Veiby OP, McNiece IK, Blomhoff HK, Jacobsen SEW (1994). TNF-a potently enhances in vitro macrophage production from primitive murine hematopoietic progenitor cells in combination with Stem Cell Factor and Interleukin-7: novel stimulatory role of p55 TNF receptor. Blood 84(5):1528-1533.

45. Fahlman C, Blomhoff HK, Veiby OP, McNiece IK, Jacobsen SEW (1994). Stem cell factor and interleukin-7 synergize to enhance early myelopoiesis in vitro. Blood 84(5):1450-1456.

46. Andrews RG, Briddell RA, Knitter GH, Rowley SD, Appelbaum FR, McNiece IK (1995). Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 85(1):15-20.

47. Yan X-Q, Hartley C, McElroy P, Chang A, McCrea C, McNiece I (1995). PBPC mobilized by rhG-CSF plus rrSCF contain long-term engrafting cells capable of cellular proliferation for over 2 years as demonstrated by serial transplantation in mice. Blood 85(9):2303-2307.

48. Yan X-Q, Lacey D, Fletcher F, Hartley C, McElroy T, Sun Y, Xia M, Mu S, Saris C, Hill D, Hawley RG, McNiece I (1995). Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 86(11):4025-4033.

49. Purdy MH, Hogan CJ, Hami L, McNiece I, Franklin W, Jones W, Bearman S, Berenson RJ, Cagnoni PJ, Heimfeld S, Shpall EJ (1995). Large scale ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation. J. Hematotherapy 4:515-525.

50. Suzuki A, Andrew DP, Gonzalo J-A, Fukumoto M, Spellberg J, Hashiyama M, Takimoto H, Gerwin N, Webb I, Molineux G,McNiece I, Ley K, Butcher E, May WS, Greaves MF, Amakawa R, Tada Y, Wakeman A, Suda T, Guiterez-Ramos J-C, Mak TW (1996). CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kd protein. Blood 87(9):3550-3562.

51. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK (1996). Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 88(1):366-376.

52. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley R, McNiece IK (1996). A model of myelofibrosis and osteosclerosis in mice over-expressing MGDF (mpl-ligand): reversal of disease by bone marrow transplantation. Blood 88(2):402-409.

53. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK (1996). Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 88(4):1509-1514.

54. Juan TS-C, McNiece IK, Jenkins NA, Gilbert DJ, Copeland NG, Fletcher FA (1996). Molecular characterization of mouse and rat CPP32B gene encoding a cysteine protease resembling interleukin-1B converting enzyme and CED-3. Oncogene 13:749-755.

55. Andrews RG, Winkler A, Myerson D, Briddell RA, Knitter GH, McNiece IK, Hunt P (1996). Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons. Stem Cells 14:661-677.

56. Molineux G, Hartley C, McElroy P, McCrea C, McNiece I (1997). An analysis of the effects of combined treatment with rmGM-CSF and PEGrHuMGDF in murine bone marrow transplant recipients. Stem Cells 15(1):43-49.

57. McNiece I, Briddell R, Stoney G, Kern B, Recktenwald D, Miltenyi S (1997). Large scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. J. Hematotherapy 6(1):5-11.

58. Juan TS-C, McNiece IK, Argento JM, Jenkins NA, Gilbert DJ, Copeland NG, Fletcher FA (1997). Identification and mapping of Lice2, a cysteine protease resembling CPP32B, Interleukin-1B converting enzyme, and CED-3. Genomics 40(1):86-93.

59. Briddell R, Kern BP, Zilm KL, Stoney GB, McNiece I (1997). Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. J. Hematotherapy 6:145-150

60. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyers M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J (1997). Recombinant methionyl human stem cell factor (r-metHuSCF) and Filgrastim for PBPC mobilization and transplantation in Non-Hodgkin's lymphoma patients - results of a Phase I/II trial. Blood 89(9):3136-3147.

61. Molineux G, McCrea C, Yan XQ, McNiece I (1997). Flt-3 ligand synergises with G-CSF to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89(11):3998-4004.

62. Juan TS-C, McNiece IK, Argento JM, Sun Y, Lacey D, Hartley C, McElroy T, Yan XQ, Fletcher F (1997). Chronic expression of FLT3 ligand results in increased circulating white cell levels and abnormal cellular infiltrates associated with splenic fibrosis. Blood 90(1):76-84.

63. Hogan CJ, Shpall EJ, McNulty O, McNiece I, Dick JE, Shultz LD, Keller G (1997). Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood 90(1):85-96.

64. Gehling UM, Ryder JW, Hogan CJ, Hami L, McNiece I, Franklin W, Williams S, Helm K, King J, Shpall EJ (1997). Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. Exp. Hematol. 25(11):1125-1139.

65. Koch A, Juan TS-C, Jenkins N, Gilbert DJ, Copeland NG, McNiece IK, Fletcher FA (1997). CDNA cloning and chromosomal mapping of mouse fast skeletal muscle troponin T. Mammalian Genome 8:345-350.

66. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece IK (1997). Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 90(8):2939-2951.

67. Shapiro F, Yao T-J, Moskowitz C, Reich L, Wuest DL, Heimfeld S, McNiece IK, Gabrilove J, Nimer S, Moore MAS (1997). Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells. Clinical Cancer Res. 3:1571-1578.

68. Hogan CJ, Shpall EJ, McNiece I, Keller G (1997). Multilineage engraftment in NOD/LtSz-scis/scid mice from mobilized human CD34+ peripheral blood progenitor cells. Biology of Blood and Marrow Transplantation 3:236-246.

69. Yan XQ, Hartley C, Chen Y, McElroy P, McNiece IK (1998). Mobilized PBPC are functionally equivalent to bone marrow cells providing long-term hematopoietic reconstitution in mice. Bone Marrow Transplantation 21:975-981.

70. McNiece IK, Stoney GB, Kern BP, Briddell RA (1998). CD34+ cell selection from frozen cord blood products using the Isolex 300i and CliniMACS selection devices. J. Hematotherapy 7(5):457-461.

71. McNiece I, Kern B, Zilm K, Brunaud C, Dziem G, Briddell R (1999). Minimization of CD34+ cell enumeration variability using the procount standardized methodology. J. Hematotherapy 7(6):499-504.

72. Andrews RG, Briddell RA, Hill R, Gough M, McNiece IK (1999). Engraftment of primates with G-CSF mobilized peripheral blood Cd34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia. Stem Cells 17:210-218.

73. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher F, Cohen A, Korach E, Ulich T, McNiece I, Lockbaum P, Miller-Messana MA, Gardner S, Hunt T, Schwab G. (1999). A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp. Hematol 27(12):1724-1734.

74. Richel DJ, Johnsen HE, Canon J, Guillaume T, Schaafsma MR, Schenkeveld C, Hansen SW, McNiece I, Ewen C, Davies R, Briddell R, Gringeri A, Freeman J, Miltenyi S, Symann M (2000). Highly purified CD34+ cells isolated using magneticallyc activated cell selection provide rapid engraftment following high dose chemotherapy in breast cancer patients. BMT 25:243-249.

75. McNiece I, Kubegov D, Kerzic P, Shpall EJ, Gross S (2000). Increased expansion and differentiation of cord blood products using a two step expansion culture. Exp Hematol.28(10):1181-1186.

76. McNiece I, Jones R, Bearman S, Cagnoni P, Nieto Y, Franklin W, Ryder J, Steele A, Stoltz J, Russell P, McDermitt J, Hogan C, Murphy J, Shpall EJ (2000). Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery in breast cancer patients following high dose chemotherapy. Blood 96(9):3001-3007.

77. Dai Z, Kerzic P, Schroeder WG, McNiece IK (2001). The SRC homology 3 domain and C-terminal proline-rich sequences are required for BCR-ABL-induced ABL interactor 2 degradation, spontaneous cell migration and leukemogenesis. J. Biol. Chem. 276(31):28954-28960.

78. McNiece IK, Almeida-Porada G, Shpall EJ, Zanjani E (2002). Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long term engrafting potential. Exp. Hemat. 30(6):612-616.

79. Shpall EJ, Quinones R, Giller R, Zeng C, Baron A, Jones R, Bearman S, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK (2002). Transplantation of ex vivo expanded cord blood. BBMT 8(7):368-376.

80. Davie NJ, Crossno JT Jr, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, Carpenter TC, Brunetti JA, McNiece IK, Stenmark KR (2003). Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: potential contribution of circulating progenitor cells. Am J Physiol Lung Cell Mol Physiol 10:1152.

81. Wang JF, Qiu LY, Harrington J, McNiece IK (2003). Study of ex vivo expansion of mouse hematopoietic stem/progenitor cells and the use of them for hematopoietsis reconstitution. Zhonghua Xue Ye Xue Za Zhi 24(11):584-8.

82. Wang JF, Wu YF, Harrington J, McNiece IK (2004). Ex vivo expansions and transplantations of mouse bone marrow-derived hematopoietic stem/progenitor cells. J Zhejiang Univ Sci 5(2):157-63.

83. McNiece I, Harrington J, Turney J, Kellner J, Shpall EJ (2004). Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells (MSC). Cytotherapy 6(4):311-317.

84. Wang J-F, Wang L-J, Xiang Y, Xie C-G, Jia B-B, Harrington J, McNiece IK (2004). Mesenchymal stem/progenitor cells in human umbilical cord blood as support for ex vivo expansion of CD34+ hematopoietic stem cells and for chondrogenic differentiation. Haematologica 89(7):837-844.

85. Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, Pellom J, Slat-Vasquez V, McSweeney PA, Bearman SI, Murphy J, Jones RB (2004). Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin Cancer Res.10(15):5076-86.

86. Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L, McNiece I, Smith BD, Small D (2005). Internal tandem duplications of FLT3 gene are present in leukemic stem cells. Blood 106(2):673-80.

87. Rosinski SL, McNiece IK, Shpall EJ, Clough N, Russell P, Blunk B, Neito Y (2005). Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. BMT 36(5):425-30.

88. Heng BC, McNiece I, Haider HK, Calne RY, Cao T (2005). Possible advantages of stem cell

transfusion into the peripheral circulation, as opposed to localized transplantation in situ. Stem Cells Dev 14(4):351-3.

89. Wang LJ, Zhang YP, Wang JF, Wu YF, Xiang Y, Xie CG, Jia BB, Harrington J, McNiece IK (2005).

Biological characteristics of mesenchymal stem cells in human umbilical cord blood and their supporting capacities in ex vivo expansion of CD34+ hematopoietic stem cells. Zhomghua Xue Ye Xue Za Zhi 26(2):65-8.

90. Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J, McNiece IK (2005). Outgrowth of a

transformed cell population derived from normal human BM mesenchymal stem cell culture.

Cytotherapy 7(6):509-519.

91. Gutman JA, Shpall EJ, Nieto Y, McSweeney P, McNiece I (2006). Long-term follow-up of patients

with breast cancer transplanted with autologous ex vivo expanded peripheral blood progenitor cells.

Cell Preservation Technology 4(1):4-8.

92. Weisdorf D, Chao N, Waselenko JK, Dainiak N, Armitage JO, McNiece IK, Confer I (2006). Acute

radiation injury: Contigency planning for triage, supportive care and transplantation. Biol Blood

Marrow Transplant 12(6):672-82.

93. McNiece I, Civin C, Harrington J, Kellner J, Malehorn M, Turney J, Barber J, Jones R (2006). Ex

vivo expansion of mafosfamide (Mf) purged PBPC products. Cytotherapy 8(5):459-464.

94. Boiron JM, Dazey B, Cailliot C, Launay B, Attal M, Mazurier F, McNiece IK, Ivanovic Z, Caraux J,

Marit G, Reiffers J (2006). Large-scale expansion and transplantation of CD34+ hematopoietic

cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process

without impairment of the long-term engraftment capacity. Transfusion 46(11):1934-42.

95. Xie C, Jia B, Xiang Y, Wang L, Wang G, Huang G, McNiece IK, Wang J (2006). Support of hMSC

transduced with Tpo/FL genes to expansion of umbilical cord CD34+ cells in indirect culture. Cell Tissue Res 326:101-110.

96. Choong ML, Yang HH, McNiece I (2007). MicroRNA expression profiling during human cord

blood-derived CD34 cell erythropoiesis. Exp Hematol 35: 551-564.

97. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG,Kaur I, Marton S, Wieder ED, Worth L, Cooper LJN, Petropoulos D, Molldrem JJ, Champlin RE, Shpall EJ (2007). Delayed immune reconstitution after cord blood transplantation is characterized by impaired thympoiesis and late memory T cell skewing. Blood 110(13):4543-4551.

98. Huang GP, Pan ZJ, Jia BB, Zheng O, Xie CG, Gu JH, McNiece IK, Wang JF (2007). Ex vivo expansion and transplantation of hematopoietic stem/progenitor cells supported by mesenchymal stem cells from human umbilical cord blood. Cell Transplant 16(6):579-85.

99. Matsui W, Wang O, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ (2008). Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68(1):190-7.

100. Suh HC, Leaanansaksiri W, Ji M, Klarmann KD, Renn K, Goova J, Smith D, McNiece I, Lugthart S, Valk PJ, Delwel R, Keller JR (2008). Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene 27(42):5612-23.

101. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J, Kellner J, Zviman MM, Hatzistergos KE, Detrick B, Conte JV, McNiece I, Steenbergen C, Lardo AC, Hare JM (2009). Autologous mesenchymal stem cells produce reverse modeling in chronic ischaemic cardiomyopathy. Eur Heart J 1093(10):265.

102. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, Pattany PM, Zambrano JP, Hu Q, McNiece I, Heldman AW, Hare JM (2009). Allogeneic mesenchymal stem 1cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. PNAS 106(33):14022-7.

103. Jones R, Lebkowski J, McNiece I (2010). Stem Cells. Biol Blood Marrow Transplant 16(1), suppl 1, S115-S118. PMID: 19896546

104. Hatzistergos K, Quevedo H, Oskouei BN, Hu Q, Freigenbaum GS, Margitich IS, Mazhari R, Boyle AJ, Zambrano PJ, Rodriguez JE, Pattany PM, Valdes D, Revilla C, Heldman AW, McNiece IK, Hare JM (2010). Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 107(7):913-22. PMID: 20671238

105. Wang Y, Nathanson L, McNiece IK (2011). Differential hematopoietic supportive potential and gene expression of stromal cell lines from midgestation mouse placenta and adult bone marrow. Cell Transplantation 20(5), 707-726. PMID: 21054929

106. Trachtenberg B, Velazquez D, Williams A, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Medizabal A, Tracy M, Soto V, Byrnes J, Zambrano JP, Heldman A, Hare J (2011). Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: a randomized, double-blinded, placebo controlled study of safety and efficacy. American Heart Journal 161: (3):487-93. PMID: 21392602.

107. Williams, AR, Trachtenberg B, Velazquez DL, McNiece I , Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM (2011). Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circulation Research, 108:792-296. PMID: 21415390.

108. Oskouei BN, Lamirault G, Joseph C, Treuer AV, Landa S, Da Silva J, Hatzistergos K, Dauer M, Balkan W, McNiece I, Hare JM (2012). Increased potency of cardiac stem cell compared with bone marrow mesenchymal stem cells in cardiac repair. Stem Cells Translational Medicine 1:116-124. PMID: 23197758

109. McNiece I (2012). Stem cells and regenerative medicine. J Regenerative Medicine 1:1.

110. de Lima M, McNiece I, Robinson S, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis J, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem J, Jones R, Nieto Y, Andersson B, Shah N, Oran B, Cooper L, Worth L, Qazilbash M, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons P, Shpall E (2012). Ex-vivo co-culture with mesenchymal cells improves engraftment of cord blood. N Engl J Med 367(24):2305-2315. PMID: 23234514

111. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM. Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, de Silva J, McNiece IK, Heldman AW (2012). Comparison of allogeneic vs autologous bone marrow derived mesenchymal stem cell delivered by transendocardial injection in patients with ischemic cardiomyopathy. The POSEIDON randomized trial. JAMA 308(22):2369-79. PMID: 23117550

112. Sutsko RP, Young KC, Ribeiro A, Torres E, Rodriguez M, Hehre D, Devia C, McNiece I, Suguihara C (2012). Long term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury. Ped Res 73(1):46-53. PMID: 23138401

113. Ramachandran S, Suguihara C, Chatzistergos K, Klim J, Torres E, Huang J, Hehre D, Rodrigues C, McNiece I, Hare J, Young K (2013). Bone marrow-derived c-kit positive cells attenuate neonatal hyperoxia-induced lung injury. Cell Transplantation May 22, 2012. PMID: 23759597

114. Miranda LF, Rodrigues C, Ramachandran S, Torres E, Sanchez M, Klim J, Hehre D, McNiece I, Hare J, Suguihara C, Young KC (2013). Stem cell factor attenuates neonatal-hyperoxia-induced lung injury. Ped Res In Press. PMID: 24153399

115. Kumagi G, Pantelis T, Toh S, McNiece I, Bramlett H, Dietrich D (2013). Genetically modified mesenchymal stem cells (MSCs) promote axonal regeneration and prevent hypersensitivity after spinal cord injury. Exp Neurology July 12, 2013. PMID: 23856436

116. Mehta R, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ (2014). The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clinical Lymphoma, Myeloma and Leukemia PMID: 24169268

117. Robinson S, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martin-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper L, Najjar A, Rezvani K, Kaur I, McNiece I, Champlin R, Miller LP, Zweidler-McKay P, Shpall E (2014). Fucosylation with fucosyltransferase (FT)-VI or FT-VII improves cord blood engraftment. Cytotherapy 16(1):84-89. PMID: 24094497

118. Parmar S, Liu X, Tung SS, Robinson S, Rodriguez G, Cooper L, Yang H, Shah N, Yang H, Konopleva M, Molldrem J, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard C, Shpall EJ (2014). Third party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16(1):90-100. PMID: 24480547

119. Heldman AW, DiFede DL, Fishman JE, Trachtenberg BH, Mushtaq M, Williams AR, Zambrano JP, Suncion VY, McNiece IK, Ghersin E, Karantalis V, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Mendiazabal AM, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Rouy D, Altman P, Wong Po Foo C, de Silva J, Anderson E, Schwartz R, Hare JM (2014). Randomized, placebo-controlled, safety and efficacy trial of autologous bone marrow derived mesenchymal stem cells vs whole mononuclear bone marrow cells derived by transendocardial injection in patients with ischemic cardiomyoparthy: The TAC-HFT trial. JAMA 311(1):62-73. PMID: 24247587

120. Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Karantalis V, Mandel N, Nelson KH, Gerstenblith G, DiFede Velazquez DL, Breton E, Sitammagari K, Schulman IH, Taldone SN, Williams AR, Sanina C, Johnston PV, Brinker JA, Altman P, Mushtaq M, Tachtenberg B, Mendiazabal AM, Tracy M, Da Silva J, McNiece IK, Lardo AC, George T, Heldman AW (2014). Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally? An analysis from the POSEIDON randomized trial. Circulation Res 114(8):1292-1301. PMID: 2449819

121. Liu X, Robinson SN, Setoyama T, Tung SS, D'Abundo L, Shah MY, Yang H, Yvon E, Shah N, Yang H, Konopleva M, Garcia-Manero G, McNiece I, Rezvani K, Calin GA, Shpall EJ, Parmar S (2014). FoxP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant In Press PMID: 24710569

122. Karantalis V, DiFede D, Gerstenblith G, Pham S, Symes J, Zambrano JP, Fishman J, Pattanay P, McNiece I, Conte J, Schulman S, Wu K, Shah A, Breton E, Davis-Sproul J, Schwarz R, Feigenbaum G, Mushtaq M, Suncion VY, Lardo A, Rcih G, Borrello I, Mendizabal A, Karas TZ, Byrnes J, Lowery M, Heldman AW, Hare JM (2014). Autologous mesenchymal stem cells produce concordant improvement in regional function, tissue perfusion and fibrotic burden when administered to patients undergoing coronary bypass surgery - the PROMETHEUS trial. Circ Res 114(8):1302-1310. PMID: 24565698

123. Yavagal DR, Lin B, Raval AP, Garza PS, Dong C, Zhao W, Rangel EB, McNiece I, Rundek T, Sacco RL, Perez-Pinzon M, Hare JM (2014). Efficacy and dose-dependent safety of intra-arterial delivery of mesenchymal stem cells in a rodent stroke model. PLoS One May7:9(5)e93735. PMID: 24807059

124. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K (2014). Regulatory B-cells are enriched within the IgM memory and transitional subsets in healthy donors but deficient in chronic graft-versus-host disease. Blood In Press PMID: 25051962

125. Martin-Antonio B, Najjar A, Robinson SN, Chew C, Li S, Yvon E, Thomas MW, McNiece I, Orlowski R, Munoz-Pinedo C, Bueno C, Menendez P, Fernandez de Larrea C, Urbano-Ispizua A, Shpall EJ, Shah N (2014). Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death and Differentiation 1-12 PMID: 25051962.

126. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah S, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper L, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ (2015). Rapid engraftment of neutrophils and platelets with fucosylated cord blood. Blood March 16th In press PMID: 25778529.

127. Kellner J, Li S, Zweidler-McKay P, Shpall EJ, McNiece I (2015). Phenotypic and functional comparison of mobilized peripheral blood versus cord blood megakaryocyte populations. Cytotherapy 17(4):418-427. PMID: 25532425.

128. Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvonne E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Sphall EJ (2015). Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood 125(9):1502-1506. PMID: 25428215.

129. McNiece I, Silvajothi S, Kellner J (2015). Ex vivo expansion of suboptimal (low dose) cord blood products provides sufficient cells for transplantation of adult patients. J Stem Cell Res Ther 1(1):0001..

130. Thompson PA, Rezvani K, Hosing CM, Oran B, Oran AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ (2015). Umbilical cord blood graft engineering: challenges and opportunities. BMT Suppl 2: S55-62.

131. Kellner J, Silvajothi S, McNiece I (2015). Differential properties of human stromal cells from bone marrow, adipose, liver and cardiac tissue. Cytotherapy In Press.

132. Kellner J, Wierda W, Shpall E, Keating M, McNiece I (2015). Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL. Leuk Res In Press. PMID: 26601610.

133. Solomon J, Csontos L, Bonyhadi M, Zylberberg C, McNiece I, Kurtzberg J, Bell R, Deans R (2015). Current perspectives on the use of ancillary materials for the manufacture of cellular therapies. Cytotherapy In Press. PMID: 26596503.

134. Galipeau J, Krampera M, Barrett J, Dazzi F, Deans R, DeBruijn J, Dominicic M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MBC, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Prockop DJ, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebee L (2016). ISCT perspective on immune functional assays for Mesenchymal Stromal Cells as potency release criterion for advanced phase clinical trials. Cytotherapy In Press.

Chapters, Invited Manuscripts and Review Articles

1. Bradley TR, Hodgson GS, Kriegler AB, McNiece IK (l985). Generation of CFU‑S13 in vitro. In: Progress in Clinical and Biological Research ‑ Hematopoietic Stem Cell Physiology. E. Cronkite, N. Dainiak, R. McCaffrey, J. Palek, and P. Quesenberry (eds). Alan R. Liss, New York, Vol. l84: 39.

2. Quesenberry PJ, McNiece IK, Robinson BE, Woodward TA, Baber GB, McGrath HE, Isakson PC (1987). Stromal cell regulation of lymphoid and myeloid differentia­tion. Blood Cells 13(½):137‑145.

3. Quesenberry PJ, McNiece IK, McGrath HE, Temeles DS, Baber GB, Deacon DH (1989). Stromal regulation of hematopoiesis. Ann. N.Y. Acad. Sci. 554:116-124.

4. McNiece IK, Bertoncello I, Kriegler AB, Quesenberry PJ (1990). Colony forming cells with high proliferative potential. Int. J. Cell Cloning 8(3):146-160.

5. Quesenberry PJ, Temeles D, Stewart M, McNiece I, McGrath H, Deacon D, Srikumar K (1990). Biology of hematopoiesis and synergy amongst hematopoietic growth factors. Prog. Clin. Biol. Res. 338:1-18.

6. Quesenberry PJ, McGrath HE, McNiece IK, Temeles DS, Robinson BE (1990). Growth factor stimulation of murine megakaryocyte colony formation. Prog. Clin. Biol. Res. 356:155-165.

7. Quesenberry PJ, Temeles DS, McGrath HE, Stewart FM, Srikumar K, Deacon DH, Zhao L, McNiece IK, Woodward TA, Robinson BE (1990). Stromal regulation of haemopoiesis. In: Molecular Biology of Haemopoiesis. Sachs L, Abraham NG, Wiedermann CJ, Levine AS, Konwalinka G (eds). Intercept Ltd, England. pp 99-107.

8. Zsebo KM, Smith KA, Hartley CA, Birkett NC, Andrews RG, Martin FH, Williams DA, Broudy V, McNiece IK (1991). Biological characteristics of recombinant rat and human stem cell factor. In: Blood Cells: Their Present and Future Use in Hematology and Oncology. (M.J. Murphy, Jr., Ed.). Alpha Med press pp 194-203.

9. Quesenberry PJ, McNiece IK, Temeles D, Lowry P, Srikumar K, Kittler E, McGrath HE, Deacon D, Meyer D, Williams M, Crittenden R, Stewart FM (1991). Granulocyte colony stimulating factor: A multifunctional cytokine. In: Hematopoietic Growth Factors: Molecular Biology to Clinical Applications of rG-CSF. Quesenberry PJ, Asano S, Saito K (eds). Excerpta Medica, Ltd, Tokyo, Japan, pp 13-26.

10. McNiece IK (1992). Synergism of hematopoietic colony stimulating factors. Am. J. Ped. Hem./Onc. 14(1): 31-38.

11. McNiece IK (1992). Structure and function of interleukin-3, erythropoietin and the colony stimulating factors. In: Cytokines in Health and Disease. Kunkel SL, Remick DG (eds). Marcel Dekker, Inc. New York, pp 61-77.

12. McNiece IK, Bertoncello I, Kriegler AB, Quesenberry PJ, Zsebo KM (1992). Colony-forming cells with high proliferative potential (HPP-CFC). In: Concise Reviews in Clincal and Experimental Hematology. (M.J. Murphy, Jr., Ed.). Alpha Med Press pp 267-277.

13. Ulich TR, del Castillo J, Yi ES, Yin S, McNiece I, Yung YP, Zsebo KM (1993). Hematologic effects of stem cell factor alone and in combination with G-CSF and GM-CSF in vivo and in vitro in rodents. In: International Review of Experimental Pathology cytokine-induced pathology. B. Ryffel (ed.). Academic Press Inc., Orlando, Florida. pp 215-233.

14. McNiece IK, Briddell RA, Hartley CA, Smith KA, Andrews RG (1993). Stem cell factor enhances in vivo effects of granulocyte colony stimulating factor for stimulating mobilization of peripheral blood progenitor cells. Stem Cells 11(suppl. 2):36-41.

15. Hoffman R, Tong J, Brandt J, Traycoff C, Bruno E, McGuire BW, Gordon MS, McNiece I, Srour EF (1993). The in vitro and in vivo effects of stem cell factor on human hematopoiesis. Stem Cells 11(suppl. 2):76-82.

16. McNiece IK, Zsebo KM (1993). The role of stem cell factor in the hematopoietic system. Cancer Inv. 11(6):724-729.

17. McNiece IK, Briddell RA, Hartley CA, Andrews RG (1993). The role of stem cell factor in mobilization of peripheral blood progenitor cells: Synergy with G-CSF. Stem Cells 11(suppl. 3):83-88.

18. Andrews RG, Briddell RA, Appelbaum FR, McNiece IK (1994). Stimulation of hematopoeisis in vivo by stem cell factor. Current Science 187-196.

19. Morstyn G, Brown S, Gordon M, Crawford J, Demetri G, Rich W, McGuire B, Foote MA, McNiece I (1994). Stem cell factor is a potent synergistic factor in hematopoiesis. Oncology 51:205-214.

20. Andrews RG, Briddell RA, Appelbaum FR, McNiece IK (1994). Stimulation of hematopoiesis in vivo by stem cell factor (c-kit ligand, steel factor, mast cell growth factor). Current Opinion in Hematology 1:187-196.

21. Tong J, Gordon M, Srour E, Cooper R, Orazi A, McNiece I, Hoffman R (1994). The effect of in vivo administration of recombinant methionyl human stem cell factor on the content of hematopoietic progenitor cells present within human marrow. Eigth Symposium on Molecular Biology of Hematopoiesis 3:293.

22. McNiece IK, Zsebo KM (1994). The in vivo hematopoietic role of stem cell factor. In: Hematopoietic Growth Factors in Clinical Applications, 2nd edition. Mertelsmann & Hermann (eds). Marcel Dekker Inc. pp 381-391.

23. McNiece IK, Briddell RA, Yan X-Q, Hartley CA, Gringeri A, Foote MA, Andrews RG (1994). The role of stem cell factor in mobilization of peripheral blood progenitor cells. Leukemia and Lymphoma 15(5/6):405-409.

24. McNiece I, Shieh J-H (1994). Stem Cell Factor (SCF). In: Guidebook to Cytokines and their Receptors. N. Nicola (ed). Oxford Univ. Press, Oxford, England. pp 177-179.

25. McNiece I, Briddell R (1994). HPP-CFC assays. In: Culture of Haemopoietic Cells. Freshney RI, Pragnell IB, Freshney MG (eds). Wiley NY. pp 23-39.

26. Morstyn G, Glaspy J, Shpall EJ, LeMaistre F, Briddell R, Menchaca D, Lill M, Jones R, Tami J, Brown S, Yan XQ, McNiece I (1994). Clinical applications of filgrastim and stem cell factor in vivo and in vitro. J. Hematotherapy 3:353-355.

27. McNiece IK, Briddell RA (1995). Stem cell factor (SCF). J. Leuk. Biol. 57:14-22.

28. Sheridan WP, McNiece I (1995). Stem cell factor. In: High-Dose Cancer Therapy. 2nd edition. Armitage J, Antman K (eds.). Williams & Wilkins, Baltimore, MD. pp. 429-441.

29. McNiece IK (1995). Selection and expansion of CD34+ cells. Nouv. Rev. Fr. Hematol. 37(6):375-376.

30. McNiece IK, Briddell R (1996). Stem cell factor. In: Blood Cell Biochemistry, vol 7: Hematopoietic Cell Growth Factors and Their Receptors, Whetton AD, Gordon J (eds.). Plenium Press, NY. Pp.363-379.

31. Glaspy J, Davis M, Parker W, Foote M, McNiece I (1996). Biology and clinical potential of stem-cell factor. Cancer Chemother. Pharmacol. 38(suppl. 1):553-557.

32. McNiece IK (1997). Interleukin-3 and the colony stimulating factors. In: Cytokines in Health and Disease, 2nd edition. Remick DG and Friedland JS (eds). Marcel Dekker, Inc. NY, pp 41-51.

33. Molineux G, McNiece IK (1997). Hemopoietic growth factors and autografting. Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies. Ed Carella AM, Harwood Academic Publishers.

34. Molineux G, McNiece IK (1998). Stem cell factor. In: The Cytokine Handbook, 3rd edition. Thomson A (ed). Academic Press, San Diego. Pp 713-725.

35. Yan X-Q, McNiece IK (1998). Hematopoietic growth factors. In: Encyclopedia of Cancer. Bertino JR (ed). Academic Press.

36. Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McNiece IK (1998). Peripheral blood stem cell transplantation. In: Bailliere's Clinical Hematology. Gorin NC (ed), Paris, France. In Press.

37. Recktenwald D, Ewen C, Gibbons I, Kantor AB, Harding F, Mazanet R, McNiece I, phi-Wilson J, Sheehan K, Yeun J, Miltenyi S (1998). High yield, purity CD34 isolation with the Amgen/Amcell cell selection system. Can Res Therapy Control 7:117-122.

38. McNiece I, Jones R, Cagnoni P, Bearman P, Nieto Y, Shpall EJ (1999). Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. Hematol Cell Ther 41:82-86.

39. Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McNiece IK (1999). Peripheral blood stem cell transplantation in breast cancer. Baillieres Best Pract Res Clin Haematol 12(1-2):219-232.

40. McNiece IK (2000). New cytokines and their clinical applications. In: Advances in Allogeneic Stem Cell Transplantation. Burt R & Brush MM eds. Kluwer Academic Publishers. Pp389-405.

41. Beaudet J, McNiece IK, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McSweeney P, Shpall EJ (2000). The use of hematoietic growth factors to support patients with breast cancer recovering from dose intensive therapies. Seminars in Breast Cancer 3(3):144-152.

42. McNiece I, Briddell R (2001). Ex vivo expansion of hematopoietic progenitor cells and mature cells. Exp. Hematol. 29(1):3-11.

43. McNiece I, Shpall E (2001). Ex vivo expansion of hematopoietic cells: what cells are needed? In: Autologous Blood and Marrow Transplantation. Eds Dicke KA, Keating A. Carden Jennings Publishing, Charlottesville, VA. P3-14.

44. McNiece I (2001). Ex-vivo expansion of hematopoietic stem cells. In: Current Perspectives in Cellular Therapy 2002. Eds. Szczepiokowski Z, Snyder EL. American Association of Blood Banks, Bethesda, MD. P 48-50.

45. McNiece I, Shpall EJ (2001). Ex vivo expansion of hematopoietic cells. In: The Medical Basis for Radiation-Accident Preparedness. Ricks RC, Berger ME, O'Hara FM Jr (eds). The Parthenon Publishing Group. pp 95-107.

46. McNiece IK (2001). Ex vivo expansion of hematopoietic cells: What is the clinical need? J Hemat and Stem Cell Res 10:3;431-434.

47. McNiece IK, Briddell RA (2003). Stem cell factor. In: The Cytokine Handbook, 4th edition. Thomas

AW, Lotze MT (eds). pp 1011-1016.

48. Kelley L, McNiece I (2004). Collection and expansion of stem cells. In. Stem Cell Transplantation for AutoImmune Disease. Eds Burt RK, Marmont A.

49. McNiece I (2004). Ex vivo expansion of hematopoietic stem and progenitor cells. In: Clinical Bone Marrow and Blood Stem Cell Transplantation. Eds Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner M. Cambridge Press.

50. McNiece I (2004). Ex vivo expansion of hematopoietic cells. Exp. Hematol. 32:409-410.

51. McNiece I (2004). Ex vivo expansion of hematopoietic cells. Part II: Control of proliferation and differentiation of hematopoietic stem cells. Exp Hematol 32:692-697.

52. McNiece I (2005). Introduction to Focus on Cord Blood. Cytotherapy7(3):207-8.

53. McNiece I (2007). Subsets of mesenchymal stromal cells (MSC). Cytotherapy 9(3):301-2.

54. McNiece I (2007). Delivering cellular therapies: Lessons learned from ex vivo culture and clinical application of hematopoietic cells. Seminars in Cell and Developmental Biology 18(6):839-45.

55. McNiece I (2009). Combination cellular therapy for regenerative medicine: the stem cell niche. In: Cord Blood. In press.

56. McNiece I, Shpall EJ (2009). Ex vivo expansion of cord blood. In: Frontiers of Cord Blood Science. Eds: Subblefield P, Bhattacharya N. Springer London. Chapter 4.

57. McNiece I and Hare J (2009). The role of microenvironment stromal cells in regenerative medicine. In: Stem Cells and Regenerative Medicine. In Press.

58. Antwiler GD, Nguyen KT, McNiece IK (2009). Bioreactor design and implementation. In: Stem Cell Bioengineering. Eds: Parekkadan B, Yarmush ML. Artech House, Boston, London. Chapter 4.

59. Boyle AJ, McNiece IK, Hare JM (2010). Mesenchymal stem cell therapy for cardiac repair.
Methods in molecular biology (Clifton, N.J.) 660:65-84.

60. McNiece I, Hare J (2010). The role of microenvironments stromal cells in regenerative medicine. Stem Cells & Regenerative Medicine. H. Cheung ed, Bentham E Books.

61. McNiece IK (2011). Ex vivo expansion of cord blood hematopoietic cells. Umbilical Cord Blood: A future for regenerative medicine. S. Kadereit, G. Udolph eds. World Scientific Publishing Co, Singapore; pp77-88.

62. McNiece I (2012). Growing Cord Blood Cells for Cancer Patients. Asia Pacific Biotech News 16(7):32-35.

63. Kebriaei P, Robinson S, McNiece I, Shpall E (2013). Mesenchymal stem cells as therapy for graft versus host disease: what have we learned? In: Essentials of Mesenchymal Stem Cell Biology and its Clinical Translation. RC Zhao (ed), Springer Science and Business Media Dordrecht, p173-185.

64. McNiece I, Shpall E (2014). Does plerixafor destroy the hematopoietic progenitor cell/mesenchymal stromal cell niche? Cytotherapy 16(1): 1-2. PMID: 24373524

65. McNiece I (2014). Endothelial cells and regenerative medicine. Cytotherapy 16:1169-1170.

66. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ (2014). Concise Review: Umbilical cord blood transplantation: Past, present and future. Stem Cell Transl Med Nov 5, 2014. PMID: 25378655.

67. McNiece I (2015). Stem cells for myocardial infarction. Cytotherapy 17:243-244. PMID: 25659639

68. Olson AL, McNiece IK (2015). Novel clinical uses for cord blood derived mesenchymal stem cells. Cytotherapy Mar 25 PMID: 25819838

69. McNiece I (2015). Stem cells from cord blood and cord tissue. Stem Cell Translational Medicine 4(suppl 1), p68.

Abstracts

A1. Kriegler A, McNiece I, Bradley R, Janusewicz E, Hodgson G (l98l). Physicochemical properties and partial purification of growth factors for primitive macrophage progenitor cells with high proliferative potential. Proc. Australian Biochemical Society l4: 6l.

A2. Bradley TR, Kriegler AB, McNiece IK, Hodgson GS (l982). Some sources, properties and partial purifica­tion of synergistic activity (SA), a cofactor influencing proliferation of macrophage early progenitor cells in bone marrow. Exp.Hematol. l0 Supp ll, l0.

A3. McNiece IK, Kriegler AB, Bradley TR, Hodgson GS A growth factor for murine macrophage precursors with high proliferative potential and its relationship to interleukin­ 3. Australian and New Zealand Cell Biology Society, May l983, Sydney, Australia.

A4. McNiece IK, Kriegler AB, Bradley TR, Hodgson GS (l984). Purification of synergistic factor and interleukin‑3 from ascites fluid of WEHI‑3 tumor bearing mice. Proc. Aust. Biochem. Soc. l6: 8.

A5. McNiece IK, Bradley TR, Kriegler AB. Differen­tial response of a cell line to factors inducing large colony formation in agar cultures. Australian and New Zealand Cell Biology Society, May l984, Melbourne, Australia.

A6. McNiece IK, Kriegler AB, Bradley TR, Hodgson GS (l985). Synergistic factor and its relationship to other haemopoietic growth factors. Exp.Hematol. l3(5): 392.

A7. McNiece I, Bradley R, Kriegler A, Hodgson G. Generation of BFU‑E, HPP‑CFC, CFU‑S13, MRA and cells capable of forming IL‑3 dependent cell lines by primitive progenitor cells stimulated by the combination of CSF‑l and synergistic factor. 24th Congress of the International Society of Hematology, May l986, Sydney,, Australia.

A8. McNiece IK, Bradley TR, Kriegler AB, Hodgson GS (l986). Detection of a murine synergistic factor equivalent to the synergistic factor from human sources. Exp.Hematol. l4(6): 483.

A9. McNiece I, Bradley R, Kriegler A, Hodgson G. Studies on the relationship of the cell types stimulated by IL‑3 and CSF‑l plus SFHPlac. Control of Haemopoietic Cell Production, May l986, Melbourne, Australia.

A10. McNiece IK, Woodward T, Baber G, Hudson D, Ques­enbe­rry P Purification of a growth factor (HLGF‑1) w­hich stimulat­es primitive hematopoietic progenitor cell­s. American Cancer Society, Seventh Annual Seminar of Cancer Research. March 1987, Charlottesville, Virgini­a, USA.

A11. McNiece IK, Woodward T, Quesenbe­rry P (1987). Studies on hemolymphopoietic growth factor ‑ 1 (HLGF‑1) w­hich stimula­t­es early myeloid and lymphoid progenitor cell­s. Exp. Hematol 15(5):226.

A12. McNiece I, Stewart M, Deacon D, Quesenberry P. Synergistic interactions between hematopoietic factors as detected by in vitro murine bone marrow colony formation. Fourth Terry Fox Cancer Conference. Septemb­er 1987 Vancouver, B.C., Canada.

A13. McNiece IK, Stewart FM, Quesenberry PJ (1987). Synergistic interactions of hematopoietic growth factors on murine and human bone marrow: evidence of a human HPP‑CFC. Blood 70(5):suppl. 1 p179a.

A14. McNiece IK, Deacon DM, Baber GB, Quesenberry PJ (1987). Studies on hematopoietic growth factors produced by the stromal derived cell line TC-1: purification of HLGF-1 to apparent homogeneity. Blood 70(5):suppl. 1 p179a.

A15. Simpson L, Newberg M, Lynch K, McNiece I, Quesenberry P, Isakson P (1987). Cytokine requirements for growth and differentiation of activated B cells. FASEB J. 2(4):A876.

A16. Keller JR, Sing GK, Ellingsworth L, McNiece IK, Quesenberry PJ, Ruscetti FW (1988). The effect of transforming growth factor B1 on early hematopoietic progenitor cell growth. J. Cell. Bioch. suppl. 12A: 133.

A17. McNiece IK, Quesenberry PJ. Human IL-3 stimulates primitive human progenitor cells. Leukemia: Molecular alterations and cellular proliferation. March 16-19 1988, New Orleans, LA.

A18. Quesenberry PJ, McNiece I, McGrath E, Souza L, Baber G (1988). Multilineage stimulating effects of recombinant human granulocyte colony stimulating factor (rhG-CSF). Exp. Hematol. 16(6):477.

A19. Niskanen E, Quesenberry P, McNiece I (1988). Relationship between CFU-blast, HPP-CFC and CFU-D. Exp. Hematol. 16(6):538.

A20. McNiece IK, Andrews RG, Stewart FM, Quesenberry PJ (1988). Human bone marrow progenitor cell populations. Exp. Hematol. 16(6):550.

A21. McNiece I, Kriegler T, Quesenberry P (1989). Stimulation of primitive progenitor cells by factors produced by 5637 cells: comparison to interleukin-1 alpha. J. Cell. Biochem. suppl. 13C: p16.

A22. Robinson BE, McGrath HE, McNiece IK, Clark S, Gillis S, Quesenberry PJ (1989). Interleukin-6 (IL-6) stimulation of murine megakarycoyte colony formation. Clin. Res. 37(2):A549.

A23. Niskanen E, McNiece IK, High DV, Quesenberry PJ (1989). In vitro growth potential of cells derived from in vivo diffusion chamber cultures. Exp. Hematol.17(6): 576.

A24. McNiece IK, Fuller KH (1989). L-histidinol protection of human bone marrow colony forming cells against the cytotoxic action of 5-fluorouracil in vitro. Blood 74(7) suppl. 1, 420a.

A25. McGrath HE, Robinson BE, McNiece IK, Deacon DH, Clark S, Quesenberry PJ (1989). Interleukin-6 and multifactor stimulation of murine megakaryocyte colony formation. Blood 74(7) suppl. 1, 154a.

A26. Temeles DS, Stewart FM, McNiece IK, Meyer DL, Quesenberry PJ (1989). 5-fluorouracil modulation of human bone marrow. Blood 74(7), 112a.

A27. Ulich T, del Castillo J, McNiece I, Watson L, Yin S, Andresen J (1990). Hematologic effects of recombinant granulocyte-macrophage colony stimulating factor on the peripheral blood and bone marrow. Lab. Inv. 62(1):102.

A28. McNiece IK, Temeles DS, Fuller KH, Quesenberry PJ (1990). Further characterization of human high proliferative potential colony forming cells. Exp. Hematol. 18(6):552.

A29. Zsebo KM, Martin FH, Suggs SV, Wypych J, Lu H, McNiece I, Medlock E, Morris F, Sachdev R, Tung W, Birkett N, Smith K, Yuschenkoff V, Mendiaz E, Jacobson FH, Langley K (1990). Biological characterization of a unique early acting hematopoietic growth factor. Exp. Hematol. 18(6):703.

A30. Bertoncello I, Kriegler AB, Bradley TR, Dunlop JM, McNiece IK (1990). The effect of interleukin-6 on hemopoietic stem cell subsets resolved by rhodamine 123. Exp. Hematol. 18(6):551.

A31. Medlock ES, Yung YP, McNiece IK, Langley K, Mineo Daley C, Dubell C, Smith K, Zsebo K (1990). Role of recombinant rat stem cell factor (rrSCF) in the stimulation of the mast cell lineage. Blood 76(10) suppl. 1: 155a.

A32. McNiece I, Langley K, Zsebo K (1990). Recombinant human stem cell factor (rhSCF) synergises with CSFs and Epo to stimulate colony formation of myeloid and erythroid cells. Blood 76(10) suppl. 1:154a.

A33. Zsebo K, Suggs S, Johnson M, Langley K, Lu H, McNiece I, Jacobsen R, Birkett N, Smith K, Mendiaz E, Wypych J, Okino K, Martin F (1990). Biological characterization and cloning of the genes for rat and human stem cell factor. Blood 76(10) suppl. 1:175a.

A34. McNiece IK, Birkett NC, Smith KA, Langley K, Miles S, Hartley C, Zsebo KM (1991). Biological characterization of recombinant rat and human stem cell factor. J. Cell. Biochem. suppl. 15G:22.

A35. McNiece I, Langley K, Zsebo K (1991). Recombinant rat derived stem cell factor (rrSCF) synergises with IL-7 to stimulate primitive murine B cell progenitors in vitro. FASEB J. 5(4):A603.

A36. Zsebo KM, Birkett NC, Smith KA, McNiece IK, Andrews B (1991). Biological characterization of recombinant rat and human stem cell factor. Cytokines in hemopoeisis, Oncology, and AIDS. June 19-22, Hannover, Germany.

A37. Elliott GS, Medlock ES, Bennett L, McNiece IK, Housman J, Zsebo KM (1991). Characterization of fluorescently labeled rat and human stem cell factor. XV Congress of the International Society for Analytical Cytology. August 25-30, Bergen, Norway.

A38. McNiece I, Hartley C, Smith K, Osslund B, Zsebo K (1991). Recombinant rat stem cell factor increases survival of lethally irradiated mice. Exp. Hematol 19(6):501.

A39. Bertoncello I, Williams N, Kavnoudias H, Zsebo K, McNiece I (1991). Demonstration of the direct action of stem cell factor (SCF) in combination with CSFs on Sca-1 positive stem cells at the single cell level. Exp. Hematol. 19(6):508.

A40. Williams N, Bertoncello I, Kavnoudias H, Zsebo K, McNiece I (1991). Recombinant rat stem cell factor stimulates amplification and differentiation of purified mouse haemopoietic stem cells. Exp. Hematol. 19(6):501.

A41. Zsebo KM, Birkett NC, Smith KA, McNiece I, Andrews B (1991). Biological characterization of recombinant rat and human stem cell factor. Exp. Hematol. 19(6):584.

A42. McNiece I, Bertoncello I, Keller J, Ruscetti F, Hartley C, Zsebo K (1991). Transforming growth factor B inhibits the action of stem cell factor on mouse and human progenitor cells. Exp. Hematol. 19(6):508.

A43. Zsebo KM, Smith KA, Hartley C, McNiece I (1991). Effect of recombinant rat stem cell factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 78(10) suppl. 1:374a.

A44. McNiece I, Williams N, Kavnoudias H, Zsebo K, Bertoncello I (1991). Recombinant rat stem cell factor stimulates the amplification and differentiation of single mouse stem cells. Blood 78(10) suppl. 1:160a.

A45. McNiece I, Andrews R, Williams D, Schuening F, Zsebo K (1992). Biological characteristics of recombinant rat and human stem cell factor. Bone Marrow Transplant 10(suppl. 2):2.

A46. Briddell R, Hartley C, Moss S, McNiece I (1992). The role of stem cell factor in mobilization of peripheral blood progenitor cells (PBPC) with marrow repopulating ability in mice. Blood 80(10) suppl. 1:12a.

A47. Orazi A, Gordon MS, Neiman RS, Sledge G, Battiato L, McNiece I, Hoffman R (1993). Bone marrow effects of recombinant methionyl human stem cell factor (SCF) in patients with normal hematopoiesis. Proc. AACR 34:465a.

A48. Tong J, Gordon MS, Srour EF, Cooper R, McNiece I, Hoffman R (1993). Effects of the in vivo administration of recombinant methionyl human stem cell factor (SCF) on human hematopoietic stem cells (HSC). Proc. AACR 34:216a.

A49. Hoffman R, Tong J, Gordon MS, Srour EF, Cooper R, McNiece I (1993). The in vivo administration of recombinant methionyl human stem cell factor (SCF) expands the number of human marrow hematopoietic stem cells (HSC). Ann. of Hem.66 (suppl. II):A 76.

A50. Tong J, Gordon MS, Srour EF, Cooper R, McNiece I, Hoffman R (1993). The in vivo administration of recombinant methionyl human stem cell factor (SCF) expands the number of human marrow hematopoietic stem cells (HSC). Exp. Hematol. 21(8):1013a.

A51. McNiece I, Briddell R, Andrews R (1993). Increased mobilization of megakaryocyte progenitors in non human primates treated with rhSCF plus rhG-CSF. Exp. Hematol. 21(8):1023a.

A52. Briddell R, Hartley C, Stoney G, McNiece I (1993). SCF synergizes with G-CSF in vivo to mobilize murine peripheral blood progenitor cells with enhanced engraftment potential. Exp. Hematol. 21(8):1150a.

A53. Andrews R, Briddell R, Appelbaum FR, Knitter GH, McNiece IK (1993). Stem cell factor synergistically enhances the in vivo response to G-CSF for stimulating increased WBC and progenitor cells in blood of baboons. Exp. Hematol. 21(8):1151a.

A54. Morstyn G, Sheridan WP, Menchaca D, McNiece I (1993). Clinical potential of stem cell factor. Cytokines and Growth Factors in Cancer. Munich, October 27-30.

A55. McNiece I, Glaspy J, LeMaistre F, Briddell R, Menchaca D, Shpall EJ (1993). Effects of recombinant methyionyl human stem cell factor (rhSCF) and Filgrastim (rhG-CSF) on mobilization of peripheral blood progenitor cells: Preliminary laboratory results from a phase I/II study. Blood 82(10), suppl. 1:84a.

A56. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1993). Cloning and characterization of the complementary DNA encoding a novel human pre-B cell colony enhancing factor. Blood 82(10) suppl. 1:318a.

A57. Andrews RG, Briddell RA, Knitter GH, Opie T, Bronsdon M, Fausset P, Myerson D, Appelbaum FR, McNiece IK (1993). Low dose recombinant human stem cell factor (SCF) has a synergistic interaction with recombinant human granulocyte colony-stimulating factor (G-CSF) in vivo for stimulating the circulation of progenitor cells of multiple types in the peripheral blood of baboons. Blood 82(10) suppl. 1:232a.

A58. Yan X-Q, Briddell R, Hartley C, Stoney G, Samal B, McNiece I (1993). Mobilization of PBPC with short-term and long-term repopulating potential by the combination of SCF plus G-CSF. Blood 82(10) suppl. 1:292a.

A59. Shieh J-H, Hartley C, Chen Y-F, Briddell R, Stoney G, McNiece I (1993). Upregulation of G-CSF receptor levels on murine PBPC mobilized with rrSCF-PEG plus rhG-CSF. Blood 82(10) suppl. 1:505a.

A60. Purdy MH, Shpall EJ, Heimfeld S, Berenson RJ, McNiece I, Hami L, Jones RB (1993). Large volume ex vivo expansion of CD34 positive (+) hematopoietic progenitor cells (HPC) for transplantation. Blood 82(10) suppl. 1:652a.

A61. Briddell R, Glaspy J, Shpall EJ, LeMaistre F, Menchaca D, McNiece I (1994). Mobilization of myeloid, erythroid and megakaryocyte progenitors by recombinant human stem cell factor (rhSCF) plus Filgrastim (rhG-CSF) in patients with breast cancer. ASCO, May.

A62. Glaspy J, McNiece I, LeMaistre F, Menchaca D, Briddell R, Lill M, Jones R, Tami J, Morstyn G, Brown S, Shpall EJ (1994). Effects of stem cell factor (rhSCF) and Filgrastim (rhG-CSF) on mobilization of peripheral blood progenitor cells (PBPC) and on hematological recovery posttransplant: early results from a phase I/II study. ASCO, May.

A63. Briddell R, Glaspy J, Shpall EJ, LeMaistre F, Menchaca D, McNiece I (1994). Recombinant human stem cell factor (rhSCF) and Filgrastim (rhG-CSF) synergize to mobilize myeloid, erythroid and megakaryocyte progenitors in patients with breast cancer. Br. J. Hematol. 87(suppl 1):92.

A64. Glaspy J, McNiece I, LeMaistre F, Menchaca D, Briddell R, Lill M, Jones R, Tami J, Morstyn G, Brown S, Shpall EJ (1994). Effects of stem cell factor (rhSCF) and Filgrastim (rhG-CSF) on mobilization of peripheral blood progenitor cells (PBPC) and on hematological recovery post transplant: preliminary phase I/II study results. Br. J. Hematol 87(suppl 1):156.

A65. Shieh J-H, Chen Y-F, Briddell R, Stoney G, McNiece I (1994). High purity of blast cells in CD34 selected populations are essential for optimal ex vivo expansion of human GM-CFC. ISEH, August.

A66. Briddell R, Stoney G, Glaspy J, Shpall EJ, LeMaistre F, Menchaca D, McNiece I (1994). Peripheral blood progenitor cells (PBPC) from breast cancer patients mobilized with stem cell factor (rhSCF) plus Filgrastim (rhG-CSF) demonstrate typical in vitro growth responsiveness. ISEH, August.

A67. Briddell R, Glaspy J, Shpall EJ, LeMaistre F, Menchaca D, McNiece I (1994). Treatment of breast cancer patients with stem cell factor (rhSCF) and Filgrastim (rhG-CSF) mobilizes increased numbers of megakaryocyte progenitors. ISEH, August.

A68. Molineux G, Hartley C, Toso R, Linberg RA, Fox G, Bartley T, McNiece IK (1994). The stimulation of mouse hematopoietic progenitor cell growth by B61 (ECK ligand). Blood 84(10) suppl. 1:279a.

A69. Moskowitz C, Stiff P, Gordon M, Gabrilove J, Bayer R, Broun R, Nichols C, Ho AD, Wyers M, Nimer S, McNiece I (1994). The influence of extensive prior chemotherapy on the mobilization of peripheral blood progenitor cells (PBPC) using stem cell factor (rhSCF) and Filgrastim (metHuG-CSF) and on hematologic recovery post cyclophosphamide, BCNU, and VP-16 (CBV) in patients (pts) with relapsed non-hodgkin's lymphoma (NHL): an interim analysis. Blood 84(10) suppl. 1:107a.

A70. Shieh J-H, Chen Y-F, Briddell R, Stoney G, McNiece IK (1994). Ex vivo expansion of megakaryocytes and neutrophil progenitors from mobilized peripheral blood progenitor cells. Blood 84(10) suppl. 1:327a.

A71. Yan XQ, Hartley C, McElroy T, McNiece I (1994). Serial transplantation of SCF plus G-CSF mobilized PBPC demonstrated long term engraftment in secondary recipient mice. Blood 84(10) suppl. 1:344a.

A72. McNiece I, Glaspy J, Shpall EJ, LeMaistre F, Menchaca D, Briddell R (1994). CD34+ cells in pheresis harvest from patients mobilized by growth factors predict engraftment post transplantation. Blood 84(10) suppl. 1:348a.

A73. McNiece I, Briddell R, Shieh J-H (1995). The role of SCF in ex vivo expansion. Acta Haematologica 93:119.

A74. Yan X-Q, Lacey D, Fletcher F, Hartley C, McElroy T, McNiece I (1995). Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Acta Haematologica 93:210.

A75. McNiece IK (1995). Stem cell factor: present understanding and clinical potential. Can. J. Infect. Dis. 6, suppl. C:255C.

A76. Glaspy J, Chap L, menchaca D, Hill J, Norton L, McNiece I, Lill M (1995). Effect of prior chemotherapy on peripheral blood progenitor cell (PBPC) harvests in patients with breast cancer. ASCO 14:319.

A77. Yan XQ, Hartley C, McElroy T, McCrea C, McNiece I (1995). PBPC mobilized by rhG-CSF plus rrSCF contain long term engrafting cells capable of cellular proliferation for over 2 years as demonstrated by serial transplantation in mice. Exp. Hematol. 23(8):783a.

A78 McNiece I, Briddell R, Recktenwald D, Phi-Wilson J, Stoney G, Shpall E, Miltenyi S (1995). Large scale isolation of CD34+ expressing cells using the Amgen cell selection device results in high levels of purity and recovery. Exp. Hematol. 23(8):806a.

A79. Fletcher FA, Yan X-Q, Lacey D, Hartley C, McElroy T, Shannon B, Sun Y, Xia M, Mu S, Saris C, Hill D, McNiece I (1995). Long-term in vivo expression of MGDF (mpl-ligand) in mice induces lineage-specific growth and differentiation of megakaryocytes. Exp. Hematol. 23(8):829a.

A80. Molineux G, Hartley C, McCrea C, McNiece IK (1995). MGDF (mpl-ligand) enhances platelet recovery after bone marrow transplantation. Exp. Hematol. 23(8)829a.

A81. Molineux G, Hartley C, MCCREA C, McNiece IK (1995). Continuous subcutaneous infusion (CSI) of hematopoietic growth factors in mice. Exp. Hematol. 23(8):880a.

A82. Briddell R, Stoney G, Schuster L, Kern B, Zilm K, Glaspy J, Shpall E, LeMaistre F, McNiece I (1995). Primitive hematopoietic progenitor cells in peripheral blood harvests of patients mobilized with rhSCF plus rhG-CSF. Exp. Hematol. 23(8):751a.

A83. Shieh J-H, Chen Y-F, Briddell R, Stoney G, McNiece IK (1995). Megakaryocyte growth and development factor (c-mpl ligand) acts in combination with stem cell factor and granulocyte colony stimulating factor to expand myeloid progenitors and megakaryocytes in vitro. Exp. Hematol. 23(8):907.

A84. Sheridan W, Shpall EJ, LeMaistre F, McNiece I, Hill J, Glaspy J (1995). Clinical evaluation of stem cell factor. AACR, October, 1995.

A85. Fletcher FA, Juan TS-C, Lacey D, Yan XQ, Hartley C, McElroy T, Sun Y, Hill D, Hawley R, McNiece I (1995). Chronic over-expression of FLT3FLK2 ligand in mice results in increased circulating white cell levels and abnormal lymphoreticular cell infiltrates associated with splenic fibrosis. Blood 86(10)suppl. 1:21a.

A86. Gehling UM, Ryder JW,Hogan CJ, Hami L, McNiece I, Franklin W, Williams S, Helm K, King J, Shpall EJ (1997). Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. Exp. Hematol. 25(11):1125-1139.

A87. Shapiro F, Yao TJ, Ouerijero M, Moskowitz C, Reich L, Wuest DL, Heimfeld S, McNiece I, Gabrilove J, Nimer S, Moore MAS (1995). The proliferative potential of peripheral blood CD34+ cells inversely correlates with prior therapy. Blood 86(10)suppl.1:121a.

A88. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK (1995). Effects of treatment with MGDF and G-CSF on the acceleration of simultaneous neutrophil and platelet recovery after bone marrow transplantation in mice. Blood 86(10)suppl.1:227a.

A89. Briddell R, Zilm K, Kern B, Stoney G, Harding F, Recktenwald D, Miltenyi S McNiece I (1995). Depletion of T-lymphocyte sunsets in peripheral blood apheresis harvest from normal donors by purification of cells expressing the CD34 antigen. Blood 86(10)suppl. 1:233a.

A90. Fletcher FA, Juan T, Yan XQ, Hartley C, McElroy T, Sun Y, Hawley R, McNiece I (1995). Replacement gene therapy phenotypically corrects fat deposition defect in ob/ob mice resulting in normalized body weight. Blood 86(10)suppl.1:241a.

A91. Shieh JH, Chen YF, Molineux G, McNiece IK (1995). MGDF binding to platelets: upmodulation by MGDF in vitro. Blood 86(10)suppl.1:369a.

A92. Andrews RG, Winkler A, Woogerd P, Briddell RA, Myerson DA, Knitter GH, McNiece IK, Hunt P (1996). Recombinant human megakaryocyte growth and development factor (rHUMGDF) stimulates thrombopoiesis in normal baboons and accelerates platelet recovery after chemotherapy. Blood 86(10)suppl.1:371a.

A93. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK (1995). Megakaryocyte growth and differentiation factor (MGDF) accelerates recovery in peripheral blood progenitor cell (PBPC) transplant recipient mice. Blood 86(10)suppl.1:461a.

A94. Keller G, Hogan C, McBurney E, Hami L, Helm K, Shultz L, Dick J, McNiece I, Shpall E (1995). Transplantation of CD34+ human (hu) umbilical cord blood progenitor cells into non-obese diabetic (NOD)/severe immunodeficiency (SCID) mice. Blood 86(10)suppl.1:573a.

A95. Lourdovaris M, Unverzagt K, Smith S, Qiao X, Martinson J, Bender J, McNiece I (1995) Ex-vivo expansion of neutrophil precursors from mobilized peripheral progenitor cells. Blood 86(10)suppl.1:584a.

A96. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK (1996). Animal models of blood cell mobilization. Blood Cell Transplantation, 4th Int. Symp. Adelaide, Sth Australia, March 24-27.

A97. Weaver A, Hecht Th, Crowther D, Testa NG, Shpall E, Borkett K, McNiece I, Glaspy J (1996). Stem cell factor (r-metHuSCF) and filgrastim (r-metHuG-CSF) for mobilization of peripheral blood progenitor cells for transplantation. Br. J. Hematol. 93(suppl.2):174.

A98. Briddell RA, Kern BP, Zilm KL, McNiece IK (1996). CD34+ cell selection is necessary for optimal ex vivo expansion of umbilical cord blood cells. Br. J. Hematol. 93(suppl.2):245.

A99. Juan TS-C, McNiece I, Fletcher F (1996). Chronic over-expression of FLT3 ligand affects T cell repopulation following bone marrow transplantation in mice. Exp. Hematol. 24(9):1041.

A100. Briddell RA, Kern BP, Zilm KL, Stoney GB, McNiece IK (1996). Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. Exp. Hematol. 24(9):1055.

A101. Stoney GB, Briddell RA, Kern BP, Zilm KL, McNiece IK (1996). Clinical scale ex vivo expansion of myeloid progenitor cells and megakaryocytes under GMP conditions. Exp. Hematol. 24(9):1043.

A102. McNiece I, Briddell R, Stoney G, Kern B, Recktenwald D, Miltenyi S (1996). CD34+ cell isolation using the Amgen cell selection device. Exp. Hematol. 24(9):1041.

A103. Fletcher FA, Juan TS-C, Pelleymounter MA, Hartley C, McElroy P, Sun Y, Argento J, Yan XQ, McNiece IK (1996). Retroviral vector-mediated expression of soluble leptin induces stable dose-dependent decrease in body fat in mice. Exp. Hematol. 24(9):1055.

A104. Yan XQ, Lacey D, Chen Y, Fletcher F, Hawley R, McNiece IK (1996). A model of myelofibrosis and osteosclerosis in mice induced by over-expressing thrombopoietin (TPO): reversal of disease by BM transplantation. Exp. Hematol. 24(9):1069.

A105. Unverzagt KL, Martinson JA, Loudovaris M, Smith SL, Lee W, Berger C, Qiao X, McNiece I, Bender JG (1996). Proliferation and differentiation of CD34+ cells into neutrophil precursors: evaluation of feeding schedules and function. Exp. Hematol. 24(9):1075.

A106. Molineux G, Hartley C, McElroy P, Kerzic P, McCrea C, McNiece IK (1996). Combined treatment of murine PBPC recipients with rhG-CSF and PEG-rhMGDF to accelerate simultaneous recovery of myeloid cells and platelets. Exp. Hematol. 24(9):1097.

A107. Yan XQ, Chen Y, Hartley C, McElroy T, McNiece I (1996). Mobilization of long term repopulating cells in mice which have been previously transplanted with PBPC. Exp. Hematol. 24(9):1140.

A108. Richel D, Jihnsen H, Canon J, Schaafsma M, Schenkeveld C, Hansen S, McNiece I, Ewen C, Davies R, Miltenyi S, Guillaume T, Symann M (1996). Highly purified CD34+ cells isolated with the Amgen cell selector provide rapid engraftment following high dose chemotherapy in breast cancer patients. Blood 88(10)suppl.1:110a.

A109. Juan TS-C, McNiece I, Argento JM, Sun Y, Lacey D, McElroy T, Yan XQ, Fletcher F (1996). Chronic over-expression of FLT3 ligand affects T cell repopulation following bone marrow transplantation in mice. Blood 88(10) suppl. 1:160a.

A110. Molineux G, Hartley C, McElroy P, Kerzic P, Stoney G, McNiece IK (1996). Hematopoietic engraftment of allogeneic mouse CD34+ peripheral blood progenitor cells. Blood 88(10)suppl.1:250a.

A111. Hogan C, Shpall E, Helm K, Hami L, McNiece I, Keller G (1996). Engraftment and development of human CD34+ enriched cells from G-mobilized peripheral blood in NOD/LtSz-scid/scid (NOD/SCID) mice. Blood 88(10)suppl.1:598a.

A112. Briddell RA, Kern BP, Zilm KL, Stoney G, McNiece IK (1996). Clinically applicable GMP culture conditions for the ex vivo expansion of cord blood cells. Blood 88(10)suppl.1:602a.

A113. McNiece I, Kern B, Zilm K, Stoney G, Briddell R (1997). Minimization of the variability of CD34+ cell enumeration using the PROCOUNT progenitor cell enumeration kit. J. Hematother. 6(2):172.

A114. McNiece I, Kern B, Zilm K, Stoney G, Briddell R (1997). Clinical scale ex vivo expansion of cord blood using GMP grade reagents. ISHAGE 3rd Int. Meeting. Bordeaux, France, May 31-June 3.

A115. Yan XQ, Chen Y, Fletcher F, McNiece IK (1997). Long-term repopulating cells and progenitors in the blood of mobilized mice are eliminated by in vivo treatment of 5-U. Acta Haematologica 98(suppl.1):38a.

A116. Shieh J-H, Chen Y-F, Molineux G, McNiece IK (1997). Human fetal liver endothelial cells support hematopoiesis in vitro. Exp. Hematol. 25(8):757.

A117. Symann M, Guillaume Th, Salmon M, Briddell R, Zilm K, Canon JL, Andre M, Jurdan M, Johnsen H, Richel D, Myltenyi S, Ewen C, McNiece I (1997). Isolation of CD34+ cells with the Amgen cell selection system provides T, NK, and tumor cell depletion of peripheral blood stem cells from breast cancer patients. Exp. Hematol. 25(8):802.

A118. McNiece I, Kern B, Zilm K, Stoney G, Briddell R (1997). Minimization of the variability of CD34+ cell enumeration using the procount progenitor cell enumeration kit. Exp. Hematol. 25(8):818.

A119. Briddell RA, Stoney GB, Zilm KL, Kern BP, McNiece IK (1997). The clinical application of CD34+ cell selection and ex vivo expansion of umbilical cord blood products. Exp. Hematol. 25(8):830.

A120. Andrews RG, Briddell RA, Gough M, McNiece IK (1997). Expansion of G-CSF mobilized CD34+ peripheral blood cells (PBC) for 10 days in G-CSF, MGDF and SCF prior to transplantation decreased post-transplant neutropenia in baboons. Blood 90:10(suppl 1), 92a.

A121. Steele A, McNiece I, Hami LS, Stoltz JK, Shpall EJ (1998). Enumeration of granulocyte-macrophage colony forming cells: the negative influence of erythropoietin. J. Hematotherapy 7(3):291.

A122. Shpall EJ, Briddell R, Hami L, Gringeri A, Jones R, Bearman S, Cagnoni P, Quinones R, Giller R, Nieto Y, Roman-Unfer S, Ross M, McNiece I (1998). Transplantation of leukemic patients receiving high dose chemotherapy with ex vivo expanded cord blood cells. Biology of Blood and Marrow Transplantation 4(2), 101.

A123. McNiece I, Hami L, Jones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ (1998). Transplantation of ex vivo expanded PBPC after high dose chemotherapy results in decreased neutropenia. Blood 92(10) suppl.1:126a.

A124. Dai Z, Pendergast AM, McNiece I (1998). The degradation of ABI proteins associated with BCR-ABL-mediated transformation is a ubiquitin-dependent event which requires interaction with oncogenic ABL. Blood 92(10) suppl.1:216a.

A125. Shpall EJ, Quinones R, Hami L, Jones R, Bearman S, Cagnoni P, Giller R, Nieto Y, Roman-Unfer S, Ross M, McNiece I (1998). Transplantation of cancer patients receiving high dose chemotherapy with ex vivo expanded cord blood cells. Blood 92(10) suppl.1:646a.

A126. McNiece I, Staerz U, Shpall EJ, Kerzic P, Smith K, Hart D (1998). Differential levels of mature dendritic cells (CMRF44+ and CD14-/CD19-) in cord blood products compared to peripheral blood. Blood 92(10) suppl.1:293b.

A127. McNiece I, Jones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ (1999). Ex vivo expansion of hematopoietic cells. The Keio J of Med 24(suppl 1):A32.

A128. Shpall EJ, Quinones R, Jones R, Bearman S, Cagnoni P, Giller R, Nieto Y, McNiece I (1999). Transplantation of cancer patients receiving high dose chemotherapy with ex vivo expanded cord blood cells.Exp. Hematol.27(7) suppl 1:117.

A129. McNiece I, Staerz U, Shpall EJ, Kerzic P, Smith K, Hart D (1999). Differential levels of mature dendritic cells (CMRF44+ and CD14-/CD19-) in cord blood products compared to peripheral blood. Exp Hematol.27(7) suppl 1:45.

A130. McNiece I, Jones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ (1999). Transplantation of ex vivo expanded PBPC after high dose chemotherapy results in decreased neutropenia. Exp. Hematol.27(7) suppl1:124.

A131. McNiece I, Jones R, Bearman S, cagnoni P, Nieto Y, Murphy J, Shpall EJ (1999). Rapid engraftment of neutrophils using ex vivo expanded PBPC correlates with total nucleated cells and not CD34 cells. Blood94(10) suppl 1:554a.

A132. Hogan C, Shpall EJ, Candia J, Jones R, Bearman S, Cagnoni P, Nieto Y, Murphy J, McNiece I (1999). Ex vivo expansion of PBPC maintains SCID repopulating cells and provides rapid and durable engraftment in breast cancer patients. Blood94(10) suppl 1:555a.

A133. Dugoff L, Quinones R, Freed B, McNiece I, Jones R, Matinez C, Huser RW, Helm K, Childs C, Prothe K, Ward W, King J, Shpall EJ (1999). Randomized study of ex-utero versus in-utero cord blood collection. Blood94(10) suppl 1:568a.

A134. Rosinski S, Kerzic P, Quinones R, Shpall EJ, Malatchi M, Russell P, McDermott J, Hart D, McNiece I (1999). Allogeneic cord blood recipients have delayed immune recovery associated with a deficiency in mature activated dendritic cells. Blood 94(10) suppl 1:574a.

A135. Reiffers J, Cailliot C, Dazey B, Duchez P, Pigneux A, Attal M, Bussiere B, Gringeri A, McNiece I, Caraux J, Boiron J (1999). Abrogation of post myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34+ cells. Blood94(10) suppl 1:706a.

A136. Shpall EJ, Quinones R, Jones R, Bearman SI, Cagnoni P, Giller R, Nieto Y, Yerushalmi R, Cook B, McSweeney P, McNiece I (1999). Transplantation of adult and pediatric cancer patients with cord blood progenitors expanded ex vivo. Blood94(10) suppl 1:712a.

A137. McNiece I, Jones R, Quinones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ (2000). Transplantation of ex vivo expanded peripheral blood progenitor cells and cord blood cells. Molecular Therapy 1(5):S8.

A138. McNiece I, Shpall EJ, Kerzic P, Kurbegov D, Gross S. Improved clinical scale culture conditions for expansion of cord blood: generation of mature neutrophil cells. IHSAGE, San Diego, June 15-18, 2000.

A139. McNiece I, Hogan C, Jones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ. Do stem cells contribute to short term engraftment in transplant patients? IHSAGE, San Diego, June 15-18, 2000.

A140. Rosinski S, Kerzic P, Quinones R, Shpall EJ, Malatchi M, Russell P, McDermott J, Hart D, McNiece I. Delayed immune recovery in allogeneic recipients of ex vivo expanded cord blood correlates with DC levels. IHSAGE, San Diego, June 15-18, 2000.

A141. Yerushalmi R, McNiece I, Childs C, Shpall EJ. CD34+ peripheral blood progenitor cells (PBPC) derived dendritic cells (DC): optimal culture conditions. IHSAGE, San Diego, June 15-18, 2000.

A142. Shpall EJ, Quinones R, Jones R, Bearman S, Cagnoni P, Giller R, Nieto Y, McSweeney P, McNiece I (2000). Transplantation of adult and pediatric cancer patients with ex vivo expanded cord blood cells. Exp Hematol 28(7) suppl 1:88.

A143. Rosinski S, Kerzic P, Quinones R, Shpall EJ, Malatchi M, Russell P, McDermott J, Hart D, McNiece I (2000). Allogeneic cord blood recipients have delayed immune recovery with a deficiency in dendritic cells. Exp Hematol 28(7) suppl 1:88.

A144. McNiece I, Shpall EJ, Kerzic P, Kurbegov D, Gross S (2000). Improved clinical scale culture conditions for expansion of cord blood: generation of mature neutrophil cells. Exp Hematol 28(7) suppl 1:88.

A145. McNiece I, Hogan C, Jones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ (2000). Do stem cells contribute to short term engraftment in transplant patients? Exp Hematol 28(7) suppl 1:89.

A146. Gross S, Pyatt D, Shpall EJ, Bearman S, McNiece IK (2000). Ex vivo expansion of CD3+ cells from cord blood for use as donor lymphocyte infusions. Exp Hematol 28(7) suppl 1:89.

A147. Yerushalmi R, Shpall EJ, Childs C, McNiece I (2000). Optimal growth of dendritic cells from CD34+ requires serum containing media. Exp Hematol 28(7) suppl 1:89.

A148. Dai Z, Kerzic P, Schroeder WG, McNiece I (2000). Mutant forms of BCR-ABL defienct in inducing ABI degradation show different leukemogenic activity. Exp Hematol 28(7) suppl 1:90.

A149. Reiffers J, Cailliot C, Dazey B, Duchez P, Pigneux A. Attal M, Bussiere B, Gringeri A, McNiece I, Caraux J, Boiron JM (2000). Abrogation of post myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34+ cells. The Hematology J 1(suppl. 1):187.

A150. Shpall EJ, Quinones R, Jones R, Bearman S, Cagnoni P, Giller R, Nieto Y, McSweeney P, Murphy J, Hogan C, Gocke A, Ward W, Slat-Vasquez V, Russell P, Blunk B, Solzan M, McNiece I (2000). Transplantation of adult and pediatric cancer patients with cord blood progenitors expanded ex vivo. Blood 96(11):207a.

A151. Dai Z, Kerzic P, Schroeder WG, McNiece I (2000). Mutation of BCR-ABL prevents ABI degradation spontaneous cell migration and impaired leukemogenesis. Blood 96(11):348a.

A152. McNiece I, Shpall EJ, Kerzic P, Kurbegov D, Gross S (2000). Improved clinical scale culture conditions for expansion of cord blood: generation of mature neutrophil cells. Blood 96(11):839a.

A153. McNiece I, Candia J, Jones R, Bearman S, Cagnoni P, Nieto Y, Murphy J, Shpall EJ (2000). Long term engraftment in breast cancer patients who received ex vivo expanded PBPC. Blood 96(11):840a.

A154. McNiece I, Harrington J, MacKay A, Shroeder W, Shpall EJ, Smith A (2001). Ex vivo expansion of CB cells without CD34 selection using co-culture on MSC. Exp Hematol29(8) suppl 1: 5.

A155. McNiece IK, Almeida-Porada G, Shpall EJ, Zanjani E. Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long term engrafting potential. Blood 98(11):476a.

A156. Lobata C, Goncalves R, Lopas A, Lemos F, Brown R, McNiece IK, Cabral J, Zanjani E, Almeida-Porada MG (2001). Stromal based serum free culture system supports the ex vivo expansion/maintenance of bone marrow (BM) and cord blood (CB) hematopoietic stem cells. Blood 98(11):654a.

A157. Swartzwelder FJ, tario JD, Allison DW, Talley DL, Harrington JA, McNiece IK (2001). Evaluation of ex vivo expansion of cord blood CD34+ progenitor cells in various serum-free media. Blood 98(11):657a.

A158. McSweeney PA, Bearman SI, Jones RB, Nieto Y, Cagnoni P, McNiece IK, Slat-Vasquez V, Ward W, Shpall EJ (2001). Nonmyeloablative hematopoietic cell transplants using cord blood. Blood 98(11):666a.

A159. McNiece I, Harrington J, James RI, Shpall EJ, MacKay A, Smith A (2001). Ex vivo expansion of CB cells without CD34 selection using co-culture on MSC. Blood 98(11):851a.

A160. Rosinski S, McNiece I, Shpall E, Clough N, Russel P, McDermott J, Nieto Y (2002). Peripheral T cell levels correlate with outcome in patients undergoing autologous stem cell transplant. Exp Hematol 30(6)suppl 1:111.

A161. McNiece I, Brunetti J, Dai Z (2002). Isolation of a mast cell progenitor dependent upon SCF and IL-3: A model of stem cell signalling. Exp Hematol 30(6)suppl 1:121.

A162. Swartzwelder F, Tario JD, Allison DW, Leugers SL, Loke HN, Donahue LN, Harrington JA, McNiece IK (2002). Ex vivo expansion of CD34+ stem cells in HSCEM/Stemline ™ medium leads to increased levels of total nucleated cells and CD34+ cells. Exp Hematol 30(6)suppl 1:124.

A163. Medeiros BC, Nieto Y, Bearman SI, Shpall EJ, Jones RB, Rabinovitch R, Cagnoni P, McNiece IK, McSweeney PA (2002). Fatal aplasia and graft rejection after nonmyeloablative allografting. Blood 100(11):416a.

A164. Almeida-Porada MG, Holcombe D, Ascensao JL, McNiece IK, Zanjani ED (2002). A large animal model for allogeneic cord blood transplantation. Blood 100(11):613a.

A165. Ambler SK, James R, McNiece IK, Long CS (2003). Integration of bone marrow-derived stem cells into infarcted myocardium following ischemia-reperfusion in mice. Amer. Society of Invest Pathology, San Diego, April 15, 2003.

A166. Rosinski S, Nieto Y, Shpall EJ, McNiece IK (2003). Peripheral T cell levels correlate with outcome of patients undergoing autologous peripheral blood progenitor cell (PBPC) transplant. ISCT, Phoenix AZ, May 29th.

A167. Rosinski S, Hart D, Nieto Y, Shpall EJ, McNiece IK (2003). Peripheral blood dendritic cell levels recipients of autologous peripheral blood progenitor cells. ISCT Phoenix AZ, May 29th.

A168. Fiorino S, Bitzan J, Loper K, Szabo S, Jones R, McNiece I (2003). Evaluation of an automated viability analyzer. ISCT Phoenix AZ, May 29th.

A169. Bitzan J, Loper K, Ondo A, McNiece I, Jones R (2003). Implementation of an environmental monitoring plan for open tissue digestion. ISCT Phoenix AZ, May 29th.

A170. Rosinski S, Nieto Y, Shpall EJ, Clough N, Russell P, Blunk B, McNiece I (2003). Peripheral T cell levels correlate with outcome of patients undergoing autologous peripheral blood progenitor cell (PBPC) transplant. Exp Hematol 31(7)suppl 1:108.

A171. McNiece IK, Civin C, Harrington J, Malehorn M, Barber J, Kellner J, Jones R (2003). Ex vivo expansion of mafosfamide purged PBPC products from patients with AML. Blood 102(11):962a.

A172. Abbott BL, McSweeney P, Harrington J, McNiece IK (2003). Quantification of hematopoietic progenitor cells by real-time RT-PCR in peripheral blood stem cell allografts. Blood 102(11):420b.

A173. McNiece IK, Harrington J, Dai Z (2004). Molecular profiles of primitive mouse hematopoietic stem cells (HSC). 10th Annual Meeting of ISCT. Dublin, Ireland, May 7-10.

A174. McNiece IK, Harrington J, Kellner J, Turney J, Shpall EJ (2004). Ex vivo expansion of cord blood mononuclear cells on MSC.10th Annual Meeting of ISCT. Dublin, Ireland, May 7-10.

A175. McNiece IK, Civin C, Harrington J, Malehorn M, Barber J, Kellner J, Jones R (2004). Ex vivo expansion of mafosfamide purged PBPC products. Exp Hematol 32(7;suppl 1):75.

A176. McNiece IK, Harrington J, Kellner J, Turney J, Shpall EJ (2004). Ex vivo expansion of mononuclear cells from frozen CB products in serum defined culture using co-culture on MSC. Exp Hematol 32(7;suppl 1):67.

A177. McNiece IK, Harrington J, Dai Z (2004). Characterization of primitive mouse hematopoietic cells. Exp Hematol 32(7;suppl 1):89.

A178. Li Y, Clough N, McNiece I, Dai Z (2004). Differential regulation of ABI-1 and ABI-2 by oncogenic ABL tyrosine kinases. Exp Hematol 32(7;suppl 1):70.

A179. Shpall EJ, McNiece IK, deLima M, McMannis JD, Robinson S, Peled T, Champlin RE (2004). Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 10(10):738.

A180. Levis MJ, Murphy KM, Rosalyn P, McNiece IK, Li L, Smith BD, Small D (2004). Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 104(11):59a.

A181. Dai Z, Li Y, Clough N, McNiece I (2004). Dysregulation of actin polymerization in hematopoietic cells transformed by bcr-abl. Blood 104(11):703a.

A182. McNiece IK, Harrington J, Kellner J, Turney J, Shpall EJ (2004). Ex vivo expansion of frozen cord blood products without selection. Blood 104(11):777a.

A183. Samal B, Dai Z, McNiece IK (2005). Gene profiles of primitive hematopoietic mouse stem cells. Cytotherapy 7(suppl 1): 63a.

A184. Wang Y, Turney J, Harrington J, Kellner J, Jeong D, McNiece IK (2005). Isolation of a transformed cell population from normal marrow derived mesenchymal stem cells. Cytotherapy 7(suppl 1): 200a.

A185. McNiece IK, Nieto Y, Jones R, Shpall E (2005). Five year follow up of breast cancer patients transplanted with ex vivo expanded peripheral blood progenitor cells (PBPC). Cytotherapy 7(suppl 1):217a.

A186. Shpall EJ, de Lima M, McMannis JD, Robinson S, McNiece IK, Champlin RE (2005). Transplantation of ex vivo expanded cord blood. Third Annual International Umbilical Cord Blood Transplantation Symposium. Los Angeles, CA, June 3-4, 2005. Biol Blood and Marrow Trans 11(11):932.

A187. Choi M, Merchav S, Wnendt S, Kraus M, Ho A, Lai Y-S, McNiece I (2005). Ex-vivo expansion of thawed cord blood mononuclear cells in co-culture of bone marrow stroma or cord blood derived unrestricted somatic stem cells. Keystone Symposia: Stem Cells, Senescence and Cancer. Singapore October 25-30: abstract 126.

A188. McNiece IK, Smith D, Turney J, Fiorino S, Kellner J, Jones R (2006). Ex vivo expansion of mafosfamide purged PBPC products and transplantation in leukemia patients. Cytotherapy 8 (suppl 1):67a.

A189. McNiece IK, Turney J, Chia A, Wei H (2006). Culture of mesenchymal stem cells (MSC) under non-adherent conditions for tissue repair. Cytotherapy 8 (suppl 1):284a.

A190. Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Mazhari R, Revilla C, Zambrano JP, McNiece I, Heldman AW, Hare JM (2007). Mesenchymal stem cell therapy restores cardiac stem cell niches after acute myocardial infarction. Circ Res 101(11):5.

A191. Hatzistergos KE, Quevedo H, Oskouei BN, Zambrano JP, Hu Q, Mazhari R, Heldman AW, McNiece I, Hare JM (2008). Cardiac chimerism following intramyocardial mesenchymal stem cell transplantation. J Am Coll Cardiol 51(10) Suppl A.

A192. McNiece I, de la Portilla L, Goldschmidt L, Wang Y (2008). Generation of non adherent mesenchymal stem cells (NA-MSC) in a closed culture system for tissue repair. Cytotherapy 10(suppl 1):39a.

A193. McNiece I, Smith D, Davis J, Jones R (2008). Rapid engraftment of ex vivo expanded, mafosfamide (MF)-purged PBPC products in leukemia patients. Cytotherapy 10(suppl 1):121a.

A194. Wang Y, Goldschmidt L, McNiece I (2008). Stromal cells derived from midgestation placental provide unique support for ex vivo expansion of bone marrow hematopoietic stem/progenitor cells. Cytotherapy 10(suppl1):235a.

A195. Almeida-Porada G, Porada CD, LeBlanc C, Ascensao JL, McNiece IK, Zanjani ED (2008). MHC-matching at 5 loci results I high levels of engraftment of allogeneic cord blood (CB) hematopoietic cells (HSC) following neonatal transplantation. Blood 112(11):abstract # 1246;452a.

A196. Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Mazhari R, Zambrano JP, Valdes D, Feigenbaum GS, Rodriguez JR, Margitich IS, Zimmet JM, Revilla C, Heldman AW, McNiece I, Hare JM. Allogeneic mesenchymal stem cells in cellular cardiomyoplasty: mechanisms of cardiac repair. Circulation, Oct 2008; 118: S_306.

A197. de Lima M, McNiece I, McMannis J, Hosing C, Kebraei P, Komanduri K, Worth L, Staba S, Cooper L, Petropolous D, Lee D, Jones R, Nieto Y, Andersson B, Korbling M, Alousi A, Qazilbash M, Popat U, Khouri I, Bollard C, Leen A, Rondon G, Molldrem J, Champlin R, Simmons P, Shpall E (2009). Double cord blood transplantation (CBT) with ex-vivo expansion (exp) of one unit utilizing a mesenchymal stromal cell (MSC) platform. ASBMT, Tampa, FL, Feb 11th, 2009.

A198. McNiece I, Oskouei B, Goldschmidt L, Chatzistergos K, Hare J (2009). Stem cell factor (SCF) stimulates cardiac stem cells (CSCs) with in vivo potential. Keystone Symposium, Cardiac Disease: Development, Regeneration, and Repair. Asheville, North Carolina, March 15-20 abstract 231.

A199. McNiece I, Oskouei B, Goldschmidt L, Chatzistergos K, Hare J (2009). Stem cell factor (SCF) stimulates cardiac stem cells (CSCs) with in vivo potential. EDC Biotech 2009. New Frontiers in Cellular and Stem Cell Therapies and Tissue Engineering. Miami, FL, April 30 th, 2009.

A200. Takeuchi RM, Takeuchi LM, Hurtado M, Moon S, McNiece I, Hu Q, Hare JM (2009). Age associated responsiveness to allogeneic mesenchymal stem cell (MSC) transplantation after ischemia-reperfusion (IR) in rats . Circulation, Nov 2009; 120: S876.

A201. De Lima M, McMannis JD, Hosing C, Kebriaei P, Robinson S, Kelly D, de Padua Silva L, Fernandez-Vina M, Chiattone A, Bosque D, Rondon G, Giralt S, Cooper L, Chen JJ, Parmar S, Jones R, Andersson C, Worth L, Alousi A, McNiece IK, Komanduri KV, Simmons P, Champlin RE, Shpall EJ (2009). Rapid engraftment of neutrophils and platelets with Mesenchymal Stem Cell based cord blod (CB) expansion (EXP). Blood114(22):1318.

A202. Wang Y, Sivajothi S, Landa S, Joseph C, McNiece I (2010). Expression of microRNA (MIR) in cardiac stromal cells. Cytotherapy 12(suppl 1):9.

A203. McNiece I, Landa S, Hussein F, Yilsastigui L, Hare J (2010). CFU-F levels in bone marrow aspirates of cardiac patients treated with mesenchymal stem cells. Cytotherapy 12(suppl 1):30.

A204. McNiece I, Oskouei B, Chatzistergos K, Hare J (2010). Growth factor stimulation of cardiac stem cells (CSCs) to generate cells with in vivo potential. Cytotherapy 12(suppl 1):52.

A205. McNiece I, Oskouei B, Savajothi S, Lamirault G, Hare J (2010). Cardiac potential of bone marrow derived MSC precursors isolated upon expression of CD271. TERMIS North America 2010 Annual Conference & Exposition. Orlando, FL, Dec 5-8, 2010. Abstract 231.

A206. De Lima M, Robinson S, McMannis J, Alousi AM, Saliba RM, Munsell M, Kebriaei P, Hosing C, Parmar S, Cooper L, Shah N, Kelley S, Rondon G, Fernandez-Vina M, Maewll I, Bosque D, Bollard K, Chen JJ, McNiece IK, Komanduri KV, Nieto Y, Jones R, Andersson BS, Popat U, Champlin RE, Simmons PJ, Shpall EJ (2010). Mesenchymal stem cell (MSC) based cord blood (CB) expansion (Exp) leads to rapid engraftment of platelets and neutrophils. Blood 116(21):p 164.

A207. Williams A, Zambrano JP, Rodriguez J, Guerra D, Bonny G, McNiece I, Hare JM, Heldman AW (2010). Mergin three-dimensional cardiac MRI with electroanatomical mapping to guide transendocardial injections of mesenchymal stem cells. Circulation 122:A15947.

A208. Yavagal DR, Lin BW, Garza P, Tienlong P, Amatangelo SM, Raval AR, Perez-Pinzon M, McNiece I, Rundek T, Hare JM (2011). Efficacy of maximal tolerated dose of intra-carotid mesenchymal stem cells in reversible subacute middle cerebal artery occlusion. Neurology 76(9)suppl 4: A514.

A209. Oskouei BN, Lamirault G, Joseph C, Landa S, Dauer M, Treuer MD, Balkan W, McNiece I, Hare JM (2011). Increased potency of cardiac stem cells compared to bone marrow mesenchymal stem cells in cardiac repair. JACC 57(14): abstract E1014.

A210. Williams AR, Trachtenberg B, Velazquez DL, Altman P, Rouy D, Mendizabel A, Fishman J, Zambrano JP, McNiece I, Heldman AW, Hare JM (2011). Preliminary results from the transendocardial injections of autologous whole bone marrow and mesenchymal stem cells in ischemic heart failure (TAC-HFT) trial. JACC 57(17); abstract E242.

A211. McNiece I, Sivajothi S, Wang Y (2012). Mobilization of mesenchymal stem cells from the bone marrow to peripheral blood. Cytotherapy 14(suppl), abstract 21.

A212. Suncion VY, Ghersin E, Zambrano JP, Karantalis V, Mandel NS, Nelson KH, Fishman JE, Gerstenblith G, DiFede Velasquez DL, Breton E, Schulman IH, Sitammagari K, Johnston PV, Brinker J, Altman P, Mushtaq M, Trachtenberg B, Da Silva J, McNiece I, Lardo AC, George RT, Hare JM, Heldman AW (2013). Does transendocardial injection of mesenahcymal stem cells improve myocardial function locally, or globally? An analysis from the POSEIDON trial. ACC March 2013.

A213. McNiece I (2013). Cardiac stromal cells inhibit proliferation of tumor cells. Cytotherapy 15(45) April Supplement, S31.

A214. McNiece I, Sivajothi S (2013). Differential properties of human bone marrow and cardiac derived stromal cells supporting proliferation of hematopoietic cells. Cytotherapy 15(45) April Supplement S32.

A215. Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Dawson M, Jena B, Jackson R, Bosque D, McNiece I, Rondon G, Hackett PB, Shpall EJ, Champlin RE, Cooper LN (2013). First-in human application of sleeping beauty system for gene therapy. ASGCT meeting, May 2013.

A216. Karantalis V, DiFede DL, Gerstenblith G, Symes J, Zambrano JP, Fishman J, McNiece I, Conte J, Schulman S, Wu K, Shah A, Breton E, Davis-Sproul J, Schwarz R, Feigenbaum G, Mushtaq M, Suncion VY, Lardo A, Rich G, Borrello I, Medizabel A, Karas TZ, Byrnes J, Lowery M, Heldman A, Hare J (2013). Autologous mesenchymal stem cells produce concordant improvement in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting. AHA 2013, Dallas Tx.

A217. Hare J, DiFede DL, Zambrano JP, Fishman J, McNiece I , Wu K, Shah A, Schwarz R, Feigenbaum G, Mushtaq M, Suncion VY, Lardo A, Rich G, Medizabel A, Karas TZ, Byrnes J, Lowery M, Heldman A, (2013). Assessment of safety and efficacy of autologous mesenchymal stem cells and whole bone marrow in patients with ischemic cardiomyoparthy: The TAC-HFT trial. AHA 2013, Dallas, Tx.

A218. Parmar S, de Lima MJ, Lee DA, Worth L, Kongtim P, Petropoulos D, McNiece IK, Shpall EJ, Rondon G, Champlin RE (2013). Is there an expiration date for cord blood units in storage? ASH, New Orleans Dec 2013.

A219. Battula VL, Benito JM, Somanchi A, Duvvuri S, Hodgson L, Chen Y, Ma W, Davis RE, McNiece IK, Shpall EJ, Konopleva M, Andreeff M (2013). Bone marrow microenvironment induces stem cell-like phenotype in acute myeloid leukemia. ASH, New Orleans Dec 2013.

A220. Sarvaria A, Khoder A, Alsuliman A, Chew C, Sekine T, Cooper N, de Lavallade H, Muftuoglu M, Yvon E, Hamdi A, Alousi AM, St John L, Marin D, Stringaris K, Liu E, Molldrem J, Shah N, Parmar S, McNiece I, Champlin R, Shpall EJ, Rezvani K (2014). Immunoregulatory B cells are enriched within transitional and IgM memory B cell subsets in healthy donors but are reduced and functionally impaired in patients with chronic graft-versus-host disease. Biol Blood and Marrow Transpl 20(2, suppl 1);555.

A221. McNiece I, Sivajothi S (2014). Differential properties of stromal cells from bone marrow, adipose, cardiac and liver. Biol Blood and Marrow Transpl 20(2, suppl 1); S187.

A222. McNiece I, Yang H, Thomas M, Jun J, Miller L, Zweidler-McKay P, Shpall E (2014). Fucosylation of ex vivo expanded cord blood (CB) cells improves engraftment in NOD/SCID mice. Cytotherapy 16(4S): S17.

A223. Kenriaei P, Huls H, Singh H, Olivares S, Figliola M, Maiti S, Shihuang S, Kumar PR, Jena B, Forget MA, Ang S, Rineka J, Liu T, McNiece I, Rondon G, Hackett P, Wierda WG, O'Brien S, Keating MJ, Kantarjian HM, Hosing CM, Shpall EJ, CHamplin RE, Cooper LJN (2014). Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD10-specific chimeric antigen receptor. Blood 311a.

A224. Parma S, Liu X, Yvon E, Zweidler-McCay P, Shah N, Rezvani K, McNiece I, Shpall EJ (2014). Ex vivo fucosylation enhances regulatory T cell anti-graft versus host disease potency in mice. Blood 660a.

A225. McNiece I, Shpall EJ, Li S, Keating M, Kellner J (2015). Comparison of BM stromal cells from CLL patients to normal indivudals. Cytotherapy 17(6S):S33.

A226. Kellner J, Sivajothi S, McNiece I (2015). Differential properties of human stromal cells from bone marrow, adipose, liver and cardiac tissue. Cytotherapy 17(6S):S37.

A227. Kellner J, Li S, Zweidler-McKay P, Shpall EJ, McNiece I (2015). Phenotypic and functional comparison of megakaryocyte population in mobilized peripheral blood versus umbilical cord blood. Cytotherapy 17(6S):S64.

A228. Kellner J, Li S, Shpall EJ, McNiece I (2015). Defining the megakaryocyte lineage to support development of improved cord blood megakaryocyte expansion protocols. Cytotherapy 17(6S):S65.

A229. Kebriaei P, Ciurea SO, Huls MH, Singh H, Olivares S, Su S, Figliola MJ, Kumar P, Jena B, Forget MA, Ang S, Jackson R, Liu T, McNiece IK, Rondon G, Hackett P, Kantarjian HM, Lee DA, Popat UR, Alousi A, Oran B, Shah N, Hosing C, Marin D, Rezvani K, Shpall EJ, Champlin RE (2015). Pre-emptive donor lymphocyte infusion with CD19-directed, CAR-modified T cells infused after allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies. American Society of Hematology, Orlando FL, Dec 5-8, abstract 862.

A230. Shah N, Li L, Kaur I, McCarty J, Yvon E, Shiam H, Muftuoglu M, Liu E, Sobieski C, Orlowski RZ, Cooper L, Lee DA, Parmar S, Cao K, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard CM, McNiece IK, Qazilbash M, Champlin RE, Rezvani K, Shpall EJ (2015). Infusion of ex vivo expanded allogeneic cord blood-derived natural killer cells in combination with autologous stem cell transplantation for multiple myeloma: Results of a phase I study. American Society of Hematology, Orlando FL, Dec 5-8, abstract 929.

A231. Mehta R, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat UR, Kebriaei P, Champlin RE, McNiece IK, De Lima M, Skerrett D, Burke E, Shpall EJ, Oran B (2015). Ex vivo mesenchymal precursor cell-expanded cord blood transplantation following reduced intensity conditioning regimens. American Society of Hematology, Orlando FL, Dec 5-8, abstract 1190.

Invited Presentations

1. McNiece IK, Temeles DS, Fuller KH, Quesenberry PJ. Characterization of primitive hematopoietic stem cells in human bone marrow. Third International Conference, the National Disease Research Interchange. Washington D.C., September 17-18, 1990.

2. McNiece I. Stem cell factor, IL-7 and pre-B cells. European Network of Immunology Institutes Turku, Finland 8-9th June, 1991.

3. Zsebo KM, Smith KA, Birkett NC, Andrews RG, McNiece IK. Biological characteristics of recombinant rat and human stem cell factor. Beijing Blood Cell Growth Factors Symposium, Beijing, China, August 21-24, 1991.

4. McNiece IK. Synergism of hematopoietic growth factors. Am. Soc. of Ped. Hem/Onc. 4th Annual Meet., Chicago, Sept. 12-14, 1991.

5. McNiece I. Biological characteristics of recombinant rat and human stem cell factor. Inter. Symposium on High-Dose Chemotherapy and Stem Cell Transplantation in Solid Tumors. Berlin, Germany 4-6th May, 1992.

6. McNiece IK. Biological characteristics of recombinant rat and human stem cell factor. Second International Freiburg Symposium on Molecular Hematology. Freiburg, Germany, June18-20, 1992.

7. McNiece IK. Biological characteristics of recombinant rat and human stem cell factor.38th Harden Conference. Wye, Kent, England. 7-11th Sept., 1992.

8. McNiece I. Early clinical evaluation of recombinant methionyl human stem cell factor. Advances in Bone Marrow Transplantation. Boston, Oct. 19-20, 1992.

9. McNiece I, Briddell R, Hartley C, Andrews R. Stem cell factor mobilization of peripheral blood progenitor cells (PBPC). Fourth Int. Conference of Anticancer Research. Rethymnon, Crete, Greece, Oct. 21-25, 1992.

10. McNiece I. In vivo biology of SCF in rodents. Stem Cell Factor and Related Cytokines in Bone Marrow Congenital Dysplasias. Cattolica, Italy. March 8-9, 1993.

11. McNiece I. Stem cell factor - the story so far. British Society of Hematology Symposium, Bournemouth, UK. April 21st, 1993.

12. McNiece I, Briddell R, Hartley C, Stoney G, Andrews R. SCF synergizes with G-CSF in vivo to mobilize peripheral blood progenitor cells with enhanced engraftment potential. Molecular Biology of Hematopoiesis, 8th Symposium. Basel Switzerland. July 9-13, 1993.

13. McNiece I. The role of stem cell factor in mobilization of peripheral blood progenitor cells. Autografting for CML. Portofino, Italy, August 19-20, 1993.

14. McNiece IK. The biology of stem cell factor. 1st Int. Symp. Cytokines in BMT. Christchurch, NZ. Sept. 6-9, 1993.

15. McNiece IK, Briddell RA, Hartley CA, Yan X-Q, Shieh J-H, Andrews RG. Clinical applications of stem cell factor. 1st Int. Symp. Cytokines in BMT. Christchurch, NZ. Sept. 6-9, 1993.

16. McNiece I. The use of recombinant human stem cell factor in vivo and in vitro. Transplantation Society of Australia and New Zealand, Canberra, Australia April 20 -21, 1994.

17. McNiece I. The role of stem cell factor and granulocyte-colony stimulating factor in mobilizing peripheral blood progenitor cells. 3rd Annual Conference on Bone Marrow Transplantation and Application of CSFs in Children. Orange County, California, April 29, 1994.

18. McNiece I. Stem cell factor. 4th Int. Pediatric Hem/Onc meeting. Edinburgh, UK, May 25-27, 1994.

19. McNiece I. Ex vivo expansion of myeloid and megakaryocyte progenitors using a reproducible and clinically applicable static culture system. 3rd Int. Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation, San Diego, March 16-18, 1995.

20. McNiece I. The clinical use of the stem cell factor in vivo and in vitro. 3rd Int. Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation, San Diego, March 16-18, 1995.

21. McNiece I. Selection and expansion of CD34+ cells. Le Futur De La Greffe De Cellules Souches Hematopoietiques. La Sorbonne, Paris. April, 1995.

22. McNiece I. Ex vivo expansion of myeloid and megakaryocyte progenitors using a reproducible and clinically applicable static culture system. Cord Blood Stem Cells. Martha's Vineyard, MA May 1995.

23. McNiece I. CD34+ cell selection using the Amcell device. Blood Cell Transplantation, 4th Int. Symp.. Adelaide, Sth. Australia, March 24-27, 1996.

24. McNiece I. Hematopoietic growth factor expansion of stem cells. Blood Cell Transplantation, 4th Int. Symp.. Adelaide, Sth. Australia, March 24-27, 1996.

25. McNiece I. Ex vivo manipulation of CD34+ cells from peripheral blood and cord blood. Int. Symp. For Stem Cell Regulation. Tokyo, Japan, Sept. 26-27, 1996.

26. McNiece IK. Ex vivo cell therapy for hematopoietic reconstitution. Cell and Tissue Bioprocessing Conf. Kansas City, MI. Sept 9-12, 1996.

27. McNiece I. Stem Cell Factor. Cytokines and Growth Factors in Hematology and Oncology. Atlanta, Georgia. November 14-16, 1996.

28. McNiece IK. The role of hematopoietic growth factors in cell therapy. Childhood Leukemia, Biological and Therapeutic Advances. Los Angeles, California. April 17-18, 1997.

29. McNiece IK. Hematopoietic growth factors in cell therapy. IBC's 3rd Conference on Hematopoietic Stem Cells. San Diego, CA June 23-24, 1997.

30. McNiece I. Clinical application of CD34+ cells selected with the Amgen cell selection system. 10th Symposium on Molecular Biology of Hematopoiesis. Hamburg, Germany, July 2-6, 1997.

31. McNiece I. Cell-manipulation. New Molecules for Graft Engineering. ISEH Symposium. Cannes, France, August 24-28, 1997.

32. McNiece I. Ex-vivo expansion of cord blood progenitors. Ex-Vivo Expansion Seminar IBMTR meeting, Keystone CO, January 10th, 1998.

33. McNiece IK, Shpall EJ. Transplantation of leukemia patients receiving high dose chemotherapy with ex vivo expanded cord blood cells. Eurocord. 3rd Eurocord transplant concerted action workshop. Annecy, France. May 18-20, 1998.

34. McNiece I, Hami L, Jones R, Bearman S, Cagnoni P, Quinones R, Nicto Y, Shpall EJ. The use of ex vivo expansion of cord blood (CB) for transplantation of leukemia patients following chemotherapy. Bormio, Italy. June 25-29, 1998.

35. McNiece I. Transplantation of ex vivo expanded cord blood cells in leukemia patients. HSA/ASBT meeting. Sydney, Australia. July 15-18, 1998.

36. McNiece I. The use of hematopoietic growth factors (HGFs) for mobilization of PBPC. Sydney, Australia. July 15-18, 1998.

37. McNiece I. Ex vivo expansion of hematopoietic stem cells. 5th Int Conference, Clinical Applications of Cytokines and Growth Factors in Hematology and Oncology. Atlanta, GO, Sept. 17-19, 1998.

38. McNiece I. Stem cell selection techniques and applications. 17th Annual Symposium Immunohematology and Blood Transfusion. NIH, Bethesda, September 24th, 25th, 1998.

39. McNiece I, Jones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ. Ex vivo expansion of hematopoietic cells.Keio University International Symposia for Life Sciences and Medicine, Cell Therapy. Keio University, Tokyo, Japan. January 21st to 23rd, 1999.

40. McNiece I. Cord blood and PBPC expansion. Hematology Society of Australia, Queensland Branch Meeting. Brisbane, Australia, March 20th, 1999.

41. McNiece I. Ex-vivo expansion of hematopoietic progenitor cell: preliminary results in breast cancer. Ateliers de Therapie Cellulaire et Genique. Paris, France March 31st to April 1st, 1999.

42. McNiece I. Expansion using classic growth factors. Workshop on Ex Vivo Expansion of Stem Cells. NIH, Bethesda, MD, July 29th, 1999.

43. McNiece I, Jones R, Hogan C, Bearman S, cagnoni P, Nieto Y, Murphy J, Shpall EJ. Ex vivo expanded PBPC provide rapid neutrophil engraftment and durable long term engraftment in breast cancer patients. Peripheral Blood Stem Cell Transplantations, Mulhouse, France, Sept 5th-8th, 1999.

44. McNiece I. Ex vivo expansion of haemopoietic progenitor cells from cord blood: clinical experience. Int Conf on Haemopoietic Stem Cell Biolgy and Transplantation. Paris, France, April 26-29, 2000.

45. McNiece I. Transplantation of ex vivo expanded peripheral blood progenitor cells and cord blood cells. Am Soc of Gene Therapy, Denver, CO, May 31-June 4th, 2000.

46. McNiece I. Transplantation of ex vivo expanded peripheral blood progenitor cells and cord blood cells. 10th Int Symposium on ABMT. Dallas, Tx July 11-14, 2000.

47. McNiece I, Jones R, Quinones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ. Transplantation of ex vivo expanded peripheral blood progenitor cells (PBPC) and cord blood cells (CB). 13th Int Symposium on Treatment of Leukemia, Lymphoma and Cancer. New York City, NY, July 14-18, 2000.

48. McNiece I. Retroviral over expression of novel genes in hematopoietic stem cells. Immunex Corp. August 2000.

49. McNiece I. Expansion in bags. Unrelated Allogeneic Cord Blood Banking and Transplantat Forum. NIH Bethesda, August 2000.

50. McNiece IK. Ex vivo expansion of hematopoietic progenitor cells and mature cells. Quality Biological Inc 7th Ex vivo Workshop. San Francisco, CA December 1st, 2000.

51. McNiece IK. Ex vivo expansion of cord blood cells. Coriell Institute, Campden, NJ. Feb 13th, 2001.

52. McNiece IK. Ex vivo cell expansion: stem cells or committed cells? The Medical Basis for Radiation Accident Preparedness IV: Focus on Clinical Care. Orlando Fl, March 6th, 2001.

53. McNiece I. Transplantation of cancer patients with ex vivo expanded cord blood cells. Recent Developments in Cord Blood Stem and Progenitor Cell Transplantation. Indianapolis, IN April 30th to May 1st, 2001.

54. McNiece I. Transplantation of ex vivo expanded cord blood cells. 6th Annual Meeting of the European Haematology Association. Frankfurt, Germany, 21-24 June, 2001.

55. McNiece I. Ex vivo expansion of hematopoietic progenitor cells and mature cells for clinical applications. Corporate Symposium 2: Future Direction of Stem Cell Expansion. ISEH meeting, Tokyo, Japan. August 25th, 2001.

56. McNiece I. Ex vivo expansion of hematopoietic progenitor cells and mature cells for clinical applications. Fukui University. Fukui, Tokyo, August 29th, 2001.

57. McNiece I. Ex vivo expansion of hematopoietic progenitor cells and mature cells for clinical applications. Fukuoka Symposium. Fukuoka, Japan. August 30th, 2001.

58. McNiece I. Engraftment of cord blood stem cells and progenitor cells in transplant patients. 5th Int symposium on In Utero Stem Cell Transplantation and Gene Therapy. Reno, Nevada, October 28 to 30, 2001.

59. McNiece I. Ex vivo expansion of hematopoietic progenitor cells from cord blood: Clinical experiences. ISCT, Barcelona , Spain, May 25-28, 2002.

60. McNiece I. Ex vivo expansion of hematopoietic stem cells. The 11th International ABMT Symposium on Stem Cell and Targeted Therapy. Arlington, TX, Dec 2-4,2002.

61. McNiece I. Stem cell proliferation and differentiation: lessons from blood cell development. Western Society for Clinical Investigation. Carmel, CA. January 30th, 2003.

62. McNiece I. Ex vivo expansion of hematopoietic cells. ISCT, Phoenix AZ, May 29-31, 2003.

63. McNiece I. Ex vivo expansion of hematopoietic cells. Hematology Fellowship Conference, NHLBI, Hematology Branch. June 2, 2004.

64. McNiece I. Cellular therapies using hematopoietic cells. 8th NUS-NUH Annual Scientific Meeting, Singapore. October, 2004.

65. McNiece I. Cellular therapies using hematopoietic cells. Mater Institute - Institutional Seminar series. Brisbane, Australia, Novermber 17th, 2004.

66. McNiece I. Cellular therapies using hematopoietic cells. 2004 Hanson Symposium, Stem cells from biology to therapy. Adelaide, Australia, November 19-21, 2004.

67. McNiece I. Role of growth factor therapies. NMDP workshop on Contingency Planning and the Transplant Community. ASBMT meeting, Keystone, CO, February 10th, 2005.

68. McNiece I. Ex vivo expansion of cord blood cells. ESH-EBMT-EUROCORD Euroconference on Stem Cell Research. Cascais, Portugal, April 15-18, 2005.

69. McNiece I. Developing cellular therapies with hematopoietic and mesenchymal stem cells. Eigth Symposium of the Biomedical Research Council. Singapore, July 21st, 2005.

70. McNiece I. Hematopoietic stem cells. Singapore Stem Cell Club, 3rd symposium. Singapore, September 15th, 2005.

71. McNiece I. Joining forces to combat cancer: Johns Hopkins in Singapore research collaboration. Health Worlds Asia, Nov 11-13, 2005. Singapore.

72. McNiece I, Shieh W, Ambinder R. Cellular and immunotherapies for treatment of cancer patients. Health Worlds Asia, Nov 11-13, 2005 Singapore.

73. McNiece I. Hematopoietic stem cells. NGS stem cell course. Matrix, Biopolis, Singapore. December 13th 2005.

74. McNiece I. Ex-vivo expansion of hematopoietic cells. International Symposium on Stem Cell and Regenerative Medicine. Navi Mumbai, India. February 27, 28, 2006.

75. McNiece I. Expansion of cord blood stem cells. Short Course in Cord Blood Transplantation, Singapore, March 31 st - April 1st, 2006.

76. McNiece I. Ex vivo expansion of mafosfamide purged PBPC products and transplantation in leukemia patients. ISCT 2006, Workshop on Clinical Trials in HSC Transplantation. Berlin, Germany, May 4-7, 2006.

77. McNiece I. Production of Cellular Products for Therapeutic Applications. Pathology Grand Rounds, Johns Hopkins University. Baltimore, MD, July 23rd, 2007.

78. McNiece I. Stem Cells and the Heart. Stem Cell Transplantation and Therapeutic Options. University of Miami, Miami, September 15, 16, 2007.

79. McNiece I. Ex vivo expansion of cord blood cells. Biology and Clinical Applications of Cord Blood Cells. Paris, France, October 19-21, 2007.

80. McNiece I. Bone marrow derived cells in angiomyogenesis and cell therapy. Cardiovascular Revascularization Therapies 2008. Washington, DC, February 11-13, 2008.

81. McNiece I. Allogeneic MSCs: The PROVACEL Trial. Cardiovascular Revascularization Therapies 2008. Washington, DC, February 11-13, 2008.

82. McNiece I. Celulas madres mesenquimales para regeneracion cardiaca. Regeneracion Del Corazon Una Nueva Frontera. Caracas, Venezuela, March 26th, 2008.

83. McNiece I. Ex vivo expansion of cord blood products. Howard P. Milstein Symposium. New York Blood Center, New York, NY, March 31 st, 2008.

84. McNiece I. Stem cells and regenerative medicine. Cell Biology Research Forum. Cell Biology and Anatomy Dept, Univ of Miami, Miami, FL. April 29th 2008.

85. McNiece I. Translation of cellular therapies to clinical practice. Microbiology and Immunology Dept, Univ of Miami, Miami, FL, April 30th 2008.

86. McNiece I. Flow cytometric analysis of mesenchymal cells. Flow Cytometry Workshop. ISCT 2008, Miami, FL, May 17th -20th, 2008.

87. McNiece I. Cord blood derived stem cells. 2 nd Annual Interdisciplinary Stem Cell Institute Symposium. Univ of Miami, FL, June 27th, 2008.

88. McNiece I. Stem cell therapies for patients with heart failure. Il Congresso Cientifico Internacional XXXVII Seminarios Medicos. Panama City, Panama, September 17th 2008.

89. McNiece I. Stem cell therapies for patients with heart failure. "Bone marrow stromal (mesenchymal stem) cells: In seek of novel therapeutic horizons". NIDCR, NIH, Bethesda, October 16th, 2008.

90. McNiece I. Cellular therapy and cardiovascular disease. CIBMTR Working Committee for Cellular Therapies, ASBMT/CIBMTR meeting, Tampa, FL, February 11th, 2009.

91. McNiece I. MSC Cell Processing Issues. NHLBI PACT sponsored workshop: Converging Concepts in Cell Therapy. Bethesda, MD, April 23-24, 2009.

92. McNiece I. Human Mesenchymal Stem Cells for Cardiac Repair. NHLBI PACT sponsored workshop: Converging Concepts in Cell Therapy. Bethesda, MD, April 23-24, 2009.

93. McNiece I. Clinical applications utilizing stem cells in regenerative medicine. III International Congress of Molecular Medicine. Istanbul, Turkey, May 5-8, 2009.

94. McNiece I. Stromal Cells: Cancer and Regenerative Medicine. Tumor Immunology Group. University of Miami, Miami, FL, October 14th, 2009.

95. McNiece I. Adult stem cells in regenerative medicine. BMT Tandem Meetings, Orlando FL, February 24-28, 2010.

96. McNiece I. Stromal cell and regenerative therapies. 2010 ISCI symposium, University of Miami, Miami, FL, May 14th, 2010.

97. McNiece I. Development of cellular products for clinical trials. Cellular Therapies with Clinical Outcomes. CellGenix symposium, ISCT meeting, Philadelphia, PN, May 24th, 2010.

98. McNiece I. Production of MSC's for cardiac trials. Cell Manufacturing 2010 Symposium. GE Global Research Center, Albany, NY, October 13, 14, 2010.

99. McNiece I. Mesenchymal stem cells (MSCs) and ischemic heart repair. 9th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases. Sonoma, CA November 17-19, 2010.

100. McNiece I. Hot topics in regenerative medicine: lessons from heart, eyes, and bones. Wound Healing Society, Dallas, Tx, April 16th, 2011.

101. McNiece I. Stem Cells. Wound Healing Society, Dallas, Tx, April 17th, 2011.

102. McNiece I. Development of new cellular therapies. Stem Cell Fellowship, Module I, Boca Raton, FL, July 30th.

103. McNiece I. Clinical Trials in Stem Cell ransplantation. Stem Cell Fellowship, Module I, Boca Raton, FL, July 30 th 2011.

104. McNiece I. Rationale - Allogeneic Stem Cell Transplantation. Stem Cell Fellowship, Module I, Boca Raton, FL, July 31 st, 2011.

105. McNiece I. Current Issues in Stem Cell Based Therapies. Stem Cell Fellowship, Module I, Boca Raton, FL, July 31 st, 2011.

106. McNiece I. MSCs for repair of ischemic cardiac tissue. Special Stem Cell Transplantation and Cellular Therapy Department Meeting, MD Anderson Cancer Center, Houston, TX, August 25th, 2011.

107. McNiece I. MSC production processes: present and future. ISCT North American Regional Meeting, Charlottesville, VA September 15-16, 2011.

108. McNiece I. Use of the CFU-F assay for MSCs in cardiovascular clinical trials. ISCT North American Regional Meeting, Charlottesville, VA September 15-16, 2011.

109. McNiece I. Clinical uses of stem cells derived from cord blood. Moderator and presenter. World Stem Cell Summit, Pasadena, CA, October 3 to 5th, 2011.

110. McNiece I. Development of cellular therapies - the role of academia. Scale -Up and manufacturing of cell-based therapies. San Diego, CA January 11-13, 2012.

111. McNiece I. Clinical Trials of Mesenchymal Stem Cells. Stem Cell Fellowship, Module V, Tampa, FL, Feb 25th, 2012.

112. McNiece I. Preparation of Platelet Rich Products for Clinical Use. Stem Cell Fellowship, Module V, Tampa, FL, Feb 25 th 2012.

113. McNiece I. Laboratory Preparation of Mesenchymal Stem Cells. Stem Cell Fellowship, Module V, Tampa, FL, Feb 25th 2012.

114. McNiece I. MSCs for Cardiac Disease. BMT Tandem Meetings, Salt Lake City, UT, Feb 13-17, 2013.

115. McNiece I. In vivo and in vitro applications of stromal cells. ISBioTech 3rd annual meeting, Rosslyn, VA, March 11-15, 2013.

116. McNiece I. The role of academia in development of cellular therapies. ISCT 2013, Auckland, New Zealand, April 22-25, 2013.

117. McNiece I. Optimization of umbilical cord blood transplantation. CellGenix expert panel "Chances and Challenges of Cell-Based Therapies". Freiburg, Germany, June 24-25, 2013.

118. McNiece I. Ex vivo expansion of cord blood cells. FOCIS 2013, Boston, MA June 27th, 2013.

119. McNiece I. The role of academia in development of cellular therapy products. ISCT Nth America Regional Meeting, Philadelphia, PA, Sept 8-11, 2013.

120. McNiece I. Optimal hematopoietic progenitor cell transplantation approach through ex-vivo MSC co-culture. World Cord Blood Congress 2013. Boston, MA, Sept 30 - Oct 1, 2013.

121. McNiece I. The effects of space relevant radiation on stem cells. Space Radiation Investigator's Workshop. Galverston, TX, Feb 13 th, 2014.

122. McNiece I. Development of autologous and allogeneic stem cell products for clinical therapies. ISBiotech 2014, Washington DC, March 10th - 13th, 2014.

123. McNiece I. Stromal stem cells and regenerative medicine. The Brown Foundation Institute of Molecular Medicine. Houston, TX, May 23rd, 2014.

124. McNiece I. Stromal stem cells and regenerative medicine. International Conference on Stem Cell Translation. Galway, Ireland, October 29th - 30th, 2014.

125. McNiece I. Tools of the trade: crucial technologies for the core lab. World Stem Cell Summit 2014, San Antonio, TX, Dec 3-5, 2014.

126. McNiece I. Biobanking challenges and strategies for developing cell-based biologics towards clinical and commercialization. World Stem Cell Summit 2014, San Antonio, TX, Dec 3-5, 2014.

127. McNiece I. Applications of cellular therapies for cancer patients. ISBioTech, Washington DC, March 9-11, 2015.

128. McNiece I. MSCs for cardiac repair. ASGCT annual meeting, New Orleans, LA, May 13-16, 2015.

129. McNiece I. Autologous versus allogeneic cellular products. Cellular Therapeutics in Trauma and Critical Care: Forging New Frontiers. San Francisco, CA, Sept 25-26, 2015.

130. McNiece I. FACT Accreditation of Cell Processing Laboratories. ISCT 2015 South and Central America Regional Meeting. Santiago, Chile, Oct 14-16, 2015.

131. McNiece I. The Real Benefits of FACT Accreditation in Translational Cell Therapies. ISCT 2015 South and Central America Regional Meeting. Santiago, Chile, Oct 14-16, 2015.

132. McNiece I. Aging - Lab to Clinic. The Christine E Lynn Symposium on Aging. West Palm Beach FL, Feb 9th 2018.

Grant Support;

COMPLETED

1. RO1#CA615082 (Shpall) Co-Investigator 7/1/97 - 6/30/02

NIH Title: Hematopoietic Progenitor Cells

The major goal of this project is to determine the clinical potential of ex vivo expanded cord blood cells and peripheral blood progenitor cells.

2. RO1# (Hogan) 7/1/99-6/30/02

Role: Co-Investigator

NIH

Characterization of human hematopoietic precursor cells.

3. NMDP (McNiece) PI 2/1/00 - 12/31/01

Natonal Marrow Donor Program Title: The role of Cord Blood T cells in Allogeneic Transplant

The goal of this project is to study immune reconstitution in recipients of ex vivo expanded CB and to evaluate the potential of CB T cells to induce an anti tumor effect.

4. Ontogeny (McNiece & Hogan) 3/1/00 - 9/30/01

Role: PI Title: Stem cell isolation

The goal of this project is to isolate purified hematopoietic stem cell populations for screening of novel genes.

5. Ontogeny (McNiece) 1/1/01 - 12/31/01

Role: PI Title: Overexpression of hedghog

The goal of this project is to overexpress the sonic hedgehog gene for studies on the biologic function of the gene in vivo.

6. Immunex Corp (McNiece) 1/1/01 - 12/31/02

Role: PI Title: Over expression of novel genes in vivo

The goal of this project is to overexpress novel genes identified from genomic screening in hematopoietic stem cells in vivo to identify potential biology of gene products.

7. Array Biopharma (McNiece) 9/1/01 - 8/30/02

Role: PI Title: Screening of small molecule compounds.

These studies are for screening of small molecules with hematopoietic activity.

8. R21 (McNiece)PI 04/01/03 - 03/31/05

NIH Title: Graft rejection

The goal of these studies is to determine the mechanism of graft failure in patients receiving non ablative stem cell transplants.

9. Cytomatrix (McNiece) 6/01/05 to 7/01/06

Title: The role of cytomatrix disks for ex vivo expansion of purged PBPC.

This project will evaluate the potential use of scaffolds from Cytomatrix to enhance ex vivo expansion.

10. RO1#CA8887801(McNiece) 1/1/01 - 04/30/07

NIH Title: Ex vivo expanded cord blood cells

Role: PI

The goal of this project is to optimize culture conditions for the ex vivo expansion of CB cells and to evaluate these conditions in clinical trials. The studies will also comprehensively evaluate immune reconstitution and the potential of cord lymphocytes in induction of an anti tumor effect.

11. RO1 HL70593-01 (McNiece) 07/01/02 - 06/30/07

NIH Title: A murine model of hematopoietic engrafting cells

Role: PI

These studies will determine the cell populations responsible for engraftment of neutrophils, platelets and lymphocytes and develop expansion conditions for optimal expansion of each population.

12. Cancer Center 5P30 CA06973-41 (Abeloff) 01/01/78 - 04/30/11

NIH Title: Hematopoietic and Therapeutic Support Core

Role: Core Director

The Cellular Therapy Core functions to provide GMP/GTP cell processing facilities and supports all cellular graft processing, freezing and manipulation for autologous and allogeneic cellular grafts for patient treatment.

13. RO1 (Leong) Co-Investigator 07/1/06 to 06/30/11

NIH Title: Biomaterials Approach to Expand Hematopoietic Cell ex vivo

Role: Co-Investigator

The goal of this project is to develop biofunctional scaffolds for generation of hematopoietic cells for clinical applications.

14. U54HL081028 Hare (PI) 1/1/06 to 12/31/10 1.2 months

NIH Title: Core E: Cellular Processing Core

Role: Core Director

Core E is charged with oversight and production of cellular products for this stem cell center grant.

15. 1P20HL101443-01 (Hare PI) 4/1/10 to 3/31/12 1.2 months

NIH

Title: Autologous adult myocardial cardioblasts to treat ischemic heart failure

Role: Co-Investigator

Goal: This project is focused on development of a clinical trial to evaluate the potential of the combined infusion of mesenchymal stem cells plus cardiac stem cells into patients with chronic myocardial ischemia.

16. Bankhead-Coley Cancer Research Program (Komanduri PI) 7/1/10 to 6/30/15 1.2 months

Florida State

Title: Improving Cord Blood Transplantation Via Expansion of Myeloid and Regulatory T Cells

Role: Co-PI

Goal: The project will evaluate ex vivo expansion techniques of cord blood cells for enhanced engraftment of myeloid and lymphoid cells in cancer patients undergoing high dose chemotherapy.

17. NASA (McNiece, PI) 07/01/12 to 11/30/14 1.8 months

Title: The effects of space radiation on stem cells and vascular and cardiac disease

Role: PI

Goal: This project will evaluate the effects of spaceflight relevant radiation on cardiac stem cells and cardiac stromal cells in vitro and in vivo.

Teaching:

1998

Departmental Seminar Dept of Immunology

Departmental Seminar Dept of Pharmacology

Frontiers in Pharmacology - lecture Dept of Pharmacology

1999

Minor lecture advisor Andrea Dowling Dept of Pharmacology

Comprehensive Examination Andrea Dowling Dept of Pharmacology

Frontiers in Pharmacology - lecture Dept of Pharmacology

Graduate student rotation Eric Mac Clarren Dept of Pharmacology

Graduate Student Mentor Steven Rosinski Dept of Pharmacology

2000

Lectures - Coagulation Pharm 6000 Dept of Pharmacology

Thesis Reviewer Andrea Dowling Dept of Pharmacology

Thesis Advisory Committee Andrea Dowling Dept of Pharmacology

Lectures - Hematopoiesis Grad Students Dept of Immunology

2001

Lectures - Coagulation Pharm 6000 Dept of Pharmacology

Thesis Advisory Committee Zach Johnson Dept of Immunology

Lectures - Hematopoiesis Grad Students Dept of Immunology

Thesis Advisory Committee Patrick Kerzic Dept of Pharmacy

2002

Thesis Advisory Committee Zach Johnson Dept of Immunology

Thesis Advisory Committee Patrick Kerzic Dept of Pharmacy

2007 - 2010

Lectures - Stem Cel Biology PIBS Univ of Miami

Thesis Advisory Committee James Timini Dept of Immunology

Thesis Advisory Committee Daniel Pelaez Dept of Bioengineering

Thesis Advisory Committee Meghan O'Connor Dept of Neurobiology

Thesis Advisor:

David Lee, M.Sc. - Northridge Univ. 1995.

Steve Rosinski, MD/PhD graduate student, 1998- 2003

Julie Candia, MSc student, 1998-2001.

Santjosh Sivajothi, PhD student, 2009 - 2016

Post Doctoral Fellows:

Training Period

Joshua Kellner 2013 to 2016

Kim Thien Nguyen, PhD 2007 to 2010

Patrick Kerzic, PhD 2005 to 2006

Gautam Dravid, PhD 2005 to 2006

Kartiki Desai, PhD 2005 to 2006

Meng Ling Choong, PhD 2005 to 2006

Melissa Wang, PhD 2004 to 2007

Dong Kee Jeong, PhD 2003 to 2005

Rohaizah James, PhD 2000 to 2002

Zonghan Dai, PhD 1998 to 1999

Sherilyn Gross, PhD 1998 to 2000

Todd Juan, PhD 1995 to 1997

Xia Qiang Yan, PhD 1993 to 1995

Service:

Head Stem Cell Biology Program University of Colorado 2001 to 2003

Director Cellular Therapy laboratory Johns Hopkins University 2003 to 2007

Member of the Advisory Board of the faculty of Medicine Johns Hopkins University, 2004 to 2006

Director Division of Biomedical Sciences Johns Hopkins in Singapore, JHU 2004 to 2006

Member of Embryonic Stem Cell Research Oversight (ESCRO) Committee JHU, 2007

Chair, Embryonic Stem Cell Research Oversight (ESCRO) Committee Univ of Miami, 2009 - 2012.

Member, Institutional Review Board#1 (MD Anderson) 2013- 2016.